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 To breast cancer patients 
“There is a crack in everything  
 That's how the light gets in.”  
 Leonard Cohen 
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Thesis at a glance 
Studies on oncoplastic breast surgery (OBS) and conventional breast-conserving 
surgery (BCS) 
Paper Aims Patients and methods Main results 
I To present and evaluate the 
strategy in the surgical planning of 
OBS in terms of different 
reconstruction methods related to 
tumour size, tumour location and 
size of the breast.  
Furthermore, to present and 
evaluate the results of surgical 
radicality in terms of resection 
margins, surgery due to insufficient 
resection margins, late positive 
sentinel nodes, i.e. positive sentinel 
node in final microscopical 
examination, and early 
postoperative complications. 
Seventy-two patients with 74 primary 
(two bilateral) breast cancers were 
treated with level II OBS from 
January 2008 to December 2010.  
Data were collected through an 
approved research database.  
Surgery was performed at three 
Danish hospitals. 
In 73 of 74 resections, the tumour was 
resected with free margins based on 
peroperative macroscopic evaluation. 
In 10 cases (14 %), peroperative 
macroscopic evaluation was corrected 
after postoperative histological 
evaluation. In seven cases (10 %), 
free margins were achieved by re-
resection, whereas three cases (4 %) 
required a mastectomy. Nine patients 
(12.3%) had surgery due to 
postoperative haematomas. Delay of 
adjuvant therapy occurred in four 
patients (6 %) due to wound healing 
problems. 
II To describe a novel technique, a 
technique using a tunnelled lateral 
fasciocutaneous flap with a skin 
island, and evaluate the results of 
immediate partial breast 
reconstruction with this technique.  
Fifteen patients, mainly with small 
breast (<250 cc), from a 
subpopulation of an OBS cohort, 
had a partial mastectomy and were 
immediately reconstructed with a 
tunnelled lateral fasciocutaneous 
flap with a skin island from January 
2008 to January 2011. 
In all cases, macroscopic free margins 
were achieved. In four patients the 
resections were microscopically too 
narrow and a re-resection was 
performed. No mastectomy was 
needed. No patients had necrosis, but 
one patient had a postoperative 
haematoma. No patients had any 
delay in the adjuvant therapy.  
III To investigate if there are 
differences in the oncological 
outcome between (OBS) and 
conventional (BCS). 
Patients treated for invasive primary 
breast cancer from 2008 to 2013 
were included. An OBS cohort 
(n=197) was compared with a 
conventional BCS cohort (n=1399). 
Data were retrieved from the DBCG 
registry. Data was evaluated by uni- 
and multivariate logistic regression 
and Cox Proportional Hazards 
analyses. 
We found a statistically significant 
lower risk of non-radical primary 
tumour excision for patients treated 
with OBS, including levels I and II, 
compared with conventional BCS. 
Regarding time to initiation of the first 
mode of adjuvant therapy, disease-
free survival, and survival, we found 
no statistically significant differences.  
IV To investigate if there are 
differences in patient-reported 
outcome among breast cancer 
patients between patients operated 
with OBS and conventional BCS. 
In 2016, patients treated with either 
OBS or conventional BCS were sent 
the Breast-Q postoperative module 
and a study-specific questionnaire 
(SSQ) yielding 96 evaluable replies 
from the OBS cohort and 631 from 
the BCS cohort. The OBS and BCS 
cohorts were compared using uni- 
and multi-variate logistic regression 
analyses for the scores for each 
domain in the Breast-Q BCT module, 
yielding odds ratios (OR) with 95% 
confidence intervals.  
There was a statistically significant 
better outcome, above vs. below the 
median, considering the HRQoL 
domain “Psychosocial Well-being” for 
patients treated with OBS as 
compared with BCS. (OR=2.15: 1.25-
3.69). No statistically significant 
differences were found for the 
domains “Physical Well-being” with the 
adjusted OR (0.83: 0.50-1.39), 
“Satisfaction with Breast” (0.95: 0.57-
1.59) or “Sexual Well-being” (1.42: 
0.78-2.58). 
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Abbreviations 
AFT Autologous Fat Transplantation
ALND Axillary Lymph Node Dissection 
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BCT Breast-Conserving Treatment
BMI Body Mass Index 
CI Confidence Interval
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Danish summary  
Brystkræft er den hyppigste kræftform blandt kvinder og udgør omkring 25% af alle 
kræfttilfælde blandt kvinder. Hver niende kvinde i Danmark vil i løbet af deres liv blive 
diagnosticeret med brystkræft. Brystkræft er sjældent hos yngre kvinder, mens antallet 
af kvinder, der får brystkræft, stiger med alderen og når et maksimum omkring 65-75 
års alderen. Omkring 4700 kvinder fik i 2016 brystkræft i Danmark og 87% af disse 
kvinder vil stadig være i live efter 5 år, mens 67000 kvinder vil leve med en tidligere 
brystkræft diagnose. Heldigvis er antallet af kvinder, der får brystkræft faldende. I 
perioden 2012 til 2016 er der sket et fald på ca. 1% i antallet af kvinder pr. år der får 
brystkræft og et fald i dødeligheden på ca. 3,5%. pr. år. Konsekvensen af denne 
udvikling er at flere kvinder vil leve med en tidligere brystkræftdiagnose – og vil leve 
længere. Det betyder, at det funktionelle og æstetiske resultat af brystkræftbehandlingen 
bliver stadig mere væsentlig. 
Den kirurgiske behandling af brystkræft er enten mastektomi, hvor hele brystet 
bortopereres, eller brystbevarende kirurgi, hvor kun kræftknuden fjernes. Behandlingen 
med begge disse behandlingsformer har den samme dokumenterede effekt på 
tilbagekomst og død af sygdommen. Omkring 70% af patienterne med brystkræft 
behandles med brystbevarende kirurgi og ca. 30% af disse kvinder ender med et 
utilfredsstillende funktionelt og æstetisk resultat af den kirurgiske behandling. 
Onkoplastik brystkirurgi er gennem de sidste årtier udviklet med det mål at forbedre 
det funktionelle og æstetiske resultat af den kirurgiske brystkræftbehandling. I 
onkoplastisk brystkirurgi anvendes teknikker kendt fra den rekonstruktive og æstetiske 
plastikkirurgi i den brystbevarende kirurgi. Når disse teknikker anvendes i den 
brystbevarende kirurgi er det muligt, at rekonstruere brystet når kræftknuden er 
bortopereret, så resultatet bliver et normalt formet bryst med et funktionelt og æstetisk 
acceptabelt resultat. På trods af at implementeringen af onkoplastisk brystkirurgi 
påbegyndtes for mere end 10 år siden i Danmark, er onkoplastisk brystkirurgi ikke fuldt 
implementeret i alle brystkirurgiske klinikker i landet. 
Målet med denne afhandling er at præsentere en strategi for implementeringen af 
onkoplastisk brystkirurgi i daglig klinisk praksis i klinikker der er engageret i den 
kirurgiske behandling af brystkræft. Endvidere er det målet at evaluere resultaterne med 
onkoplastisk brystkirurgi med tanke på om behandlingen kan gennemføres som 
skitseret i strategien, og at undersøge den onkologiske sikkerhed af behandlingen samt 
16 
hvordan patienter oplever resultatet og deres livskvalitet efter behandlingen. I 
afhandlingen indgår 4 studier. 
I det første studie præsenteres en strategi for implementationen af onkoplastisk 
brystkirurgi. I dette studie indgår 72 patienter (74 kræftknuder), der er opereret med 
onkoplasisk brystkirurgi som et samarbejde mellem plastikkirurger og brystkirurger i 
perioden 2008 til 2010. Alle patienter var registreret i en forskningsdatabase. 
Patienterne der blev behandlet med onkoplastisk brystkirurgi var udvalgt fra en bred 
gruppe af brystkræftpatienter. Patienterne blev opdelt i 4 grupper efter størrelsen af 
brystet og hvor i brystet kræftknuden var lokaliseret. De kirurgiske teknikker for 
rekonstruktion af brystet efter bortoperation af kræftknuden inkluderede teknikker, 
hvor størrelsen af brystet blev reduceret (volumen reduktion), teknikker hvor 
brystvævet blev re-arrangeret eller forskudt indenfor brystet (volumen displacement) og 
teknikker hvor defekten i brystet efter fjernelse af kræftknuden blev erstattet af væv 
hentet udenfor brystet (volumen replacement). Næsten ¾ af patienterne blev også 
opereret på det andet bryst for at opnå symmetri med det rekonstruerede bryst. Studiet 
viste at den kirurgiske teknik, der blev valgt til rekonstruktion af brystet afhang af, 
hvilken af de 4 grupper patienterne var placeret i. Med andre ord præsenteres en 
strategi, for hvordan forskellige patienter kan rekonstrueres, når de er fundet egnede til 
onkoplastisk brystkirurgi. Behandlingen blev gennemført som planlagt forud for 
operationen i alle 74 tilfælde undtaget hos en patient, hvor det ikke var muligt at fjerne 
hele kræftknuden uden at fjerne hele brystet. Der var ingen stigning i antallet af 
komplikationer til den kirurgiske behandling og ingen indikationer af at den 
adjuverende behandling blev forsinket sammenlignet med konventionel brystbevarende 
kirurgi. Sammenfattende indikerer dette studie, at implementeringen af onkoplastisk 
brystkirurgi i daglig klinisk praksis er mulig med den præsenterede strategi uden at 
svække sikkerheden af behandlingen. 
I det andet studie præsenteres en ny kirurgisk teknik – brugen af en tunnelleret 
fasciocutan lap med en hudø – til umiddelbar brystrekonstruktion i onkoplastisk 
brystkirurgi. Ved denne teknik rekrutteres væv fra brystvæggen som flyttes gennem en 
tunnel lavet i brystet til defekten i brystet efter bortoperation af kræftknuden. Lappen 
består af subkutant fedt og hud og erstatter både fylden (volumen) af kræftknuden og 
huden, der eventuelt blev fjernet sammen med kræftknuden. Der indgik 15 patienter i 
studiet med små (<250 cm3) eller mellem store bryster (250-500 cm3). Disse patienter 
var en del af patienterne i forskningsdatabasen, som også indgik i det første studie, og 
blev opereret i perioden 2008 – 2011. Ingen af patienterne blev opereret på det 
modsidige bryst for at opnå symmetri, da dette ikke var nødvendigt, fordi der blev 
anvendt en kirurgisk replacement teknik. Alle operationer blev gennemført som 
planlagt. Dog måtte 4 patienter re-opereres pga. at kræftknuden ikke var fjernet i sundt 
væv ved første operation. Brystvorte komplekset blev hos 3 patienter bortopereret 
sammen med kræftknuden og erstattet af en hudø. Fraset en enkelt komplikation, en 
blodansamling, var der ingen komplikationer til kirurgien. I studiet konkluderes det, at 
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denne kirurgiske teknik er meget brugbar og sikker, og en mulig teknik til 
brystrekonstruktion i onkoplastisk brystkirurgi.  
Målet med det tredie studie var at evaluere den onkologiske sikkerhed ved onkoplastisk 
brystkirurgi sammenlignet med konventionel brystbevarende kirurgi. Som nævnt 
ovenfor er målet med onkoplastisk brystkirurgi, at forbedre det funktionelle og 
æstetiske resultat af konventionel brystbevarende kirurgi. Imidlertid er det meget 
væsentligt at dokumentere, at den onkologiske sikkerhed ikke svækkes ved 
implementeringen af onkoplastisk brystkirurgi. Den onkologiske sikkerhed kan måles 
gennem for eksempel at undersøge, hvor ofte der ved operationen tages tilstrækkeligt 
væv væk, for at man kan være sikker på, at kræftknuden er fjernet eller ved at undersøge 
risikoen for tilbagefald af sygdommen. Kun få studier er tidligere udgivet, hvor den 
onkologiske sikkerhed undersøges ved at sammenligne onkoplastisk brystkirurgi med 
konventionel brystbevarende kirurgi. I dette studie indgik 197 patienter med brystkræft 
opereret med onkoplastisk brystkirurgi. Langt de fleste af disse patienter blev opereret 
i det sydlige Jylland. Disse patienter blev sammenlignet med 1399 patienter behandlet 
med konventionel brystbevarende kirurgi fra en anden geografisk region i Danmark, 
Region Nordjylland. Alle data blev hentet fra DBCG´s register, som er et dansk 
national brystkræft register, og alle patienter blev opereret i perioden 2008 til 2013. Til 
evaluering af den onkologiske sikkerhed undersøgte vi fire emner. Var der forskelle i 
antallet af patienter, der ikke fik bortopereret kræftknuden med frie rande (i sundt væv), 
om der var forsinkelse i påbegyndelsen af adjuverende behandling (kemo- og 
stråleterapi), om der var forskelle i antallet af patienter, der overlevede uden 
tilbagekomst af sygdommen, og om der var forskelle i overlevelse. Data for patienter, 
diagnose og kræftknude karakteristika blev hentet fra DBCG´s register og 
Dødsårsagsregisteret. Data for patienter opereret med henholdvis onkoplastik 
brystkirurgi og brystbevarende kirurgi viste, at patienter opereret med onkoplastisk 
kirurgi havde mere fremskreden brystkræft end patienter behandlet med konventionel 
brystbevarende kirurgi. Resultaterne viste en signifikant lavere risiko for ikke-radikal 
fjernelse af kræftknuden for patienter behandlet med onkoplastisk kirurgi 
sammenlignet med patienter opereret med konventionel brystbevarende kirurgi. Der 
fandtes ingen signifikante forskelle med hensyn til tidspunkt for påbegyndelse af 
ajuverende behandling, sygdom-fri overlevelse eller overlevelse. Sammenfattende 
indikerer resultaterne af dette studie, at onkoplastisk brystkirurgi er en onkologisk 
sikker behandling.  
Da målet for onkoplatisk brystkirurgi er at forbedre resultatet af brystbevarende kirurgi, 
er det væsentligt at dokumentere om resultaterne faktisk var en forbedring, set fra 
patientens synspunkt. I det fjerde og sidste studie i afhandlingen undersøges de patient-
rapporterede resultater af onkoplastisk brystkirurgi sammenlignet med konventionel 
brystbevarende kirurgi. Til måling af dette anvendte vi det validerede spørgeskema 
Breast-QTM BCT og et studie-specifikt spørgeskema. I studiet indgik de samme 
patienter som i det tredje studie, og i alt fik 1504 patienter i 2016 tilsendt 
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spørgeskemaerne enten som et brev digitalt via E-post eller som almindeligt brev. Der 
kom 96 svar fra patienter opereret med onkoplastik kirurgi og 631 svar fra patienter 
opereret med konventionel brystbevarende kirurgi, i alt 727 svar. Resultaterne viste 
statistisk signifikant bedre resultater for ”Psychosocial Well-being” for patienter 
behandlet med onkoplastisk brystkirurgi. Der var ingen signifikante forskelle for 
“Satisfaction with Breast” eller “Sexual Well Being”. Endvidere fandtes ingen forskelle 
for “Physical Well Being” trods mere omfattende kirurgi for patienter behandlet med 
onkoplastisk brystkirurgi, hvor der ofte blev opereret på begge bryster for at opnå bedre 
symmetri. Sammenfattende indikerer resultaterne af dette studie, at patienterne 
rapporterer en bedre livskvalitet efter behandling med onkoplastisk brystkirurg.  
Opsummerende viste resultaterne af studierne i afhandlingen, at implementering af 
onkoplastisk brystkirurgi i daglig klinisk praksis er gennemførlig uden at 
kompromittere den onkologiske sikkerhed og indikerer, at onkoplastisk brystkirurgi 
øger patienttilfredsheden med behandlingen sammenlignet med konventionel 
brystbevarende kirurgi 
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Swedish summary 
Bröstcancer är den vanligaste cancerformen bland kvinnor och den utgör ca 25% av all 
cancer i denna grupp. Var nionde kvinna i Danmark kommer att diagnosticeras med 
bröstcancer under sin livstid. Bröstcancer är ovanligt bland unga kvinnor, men blir 
vanligare med åldern för att nå en topp i 65-75 års åldern. Cirka 4700 kvinnor fick 
bröstcancer i Danmark 2016 men 87% av dessa kommer fortfarande att vara i livet 
efter 5 år. Samtidigt finns det 67000 kvinnor som tidigare har haft en bröstcancer. 
Mellan 2012 och 2016 minskade antalet nya bröstcancerfall med ca 1% per år och 
antalet som dog av bröstcancer minskade med hela 3,5% per år. Som en följd av detta 
kommer det att finnas allt fler kvinnor som lever vidare efter en bröstcancerdiagnos. 
Detta har gjort att man allt mer har börjat betona betydelsen av ett bra funktionellt och 
estetiskt resultat efter behandlingen för bröstcancer.  
Den kirurgiska behandlingen vid bröstcancer består antingen av mastektomi, att man 
tar bort hela bröstet, eller av bröstbevarande kirurgi där man bara tar bort tumören och 
en marginal omkring denna. Dessa behandlingar är lika bra om man jämför 
överlevnaden efter behandling. Ungefär 70% av alla behandlas med bröstbevarande 
kirurgi men man vet att ca. 30% upplever ett dåligt funktionellt eller estetiskt resultat.  
Onkoplastikkirurgi för bröst (oncoplastic breast surgery - OBS) har utvecklats under 
senare år med syfte att förbättra det funktionella och estetiska resultatet efter 
bröstkirurgi. OBS innebär att man använder tekniker hämtade från rekonstruktiv och 
estetisk bröstkirurgi. Dessa tekniker gör att det är möjligt att återskapa form och storlek 
på bröstet samtidigt med canceroperationen. Tekniken började införas i Danmark för 
mer än 10 år sedan men trots det så är den inte fullt ut implementerad i hela landet.  
Denna avhandling har flera syften. Det övergripande målet är att presentera ett koncept 
för införandet av OBS vid bröstcancerbehandling. Specifika mål är att utvärdera om 
behandlingen går att införa enligt det föreslagna konceptet, om den onkologisk säkerhet 
påverkas och hur patienterna upplever behandlingen. Avhandlingen innehåller fyra 
studier.  
I den första studien introduceras ett möjligt koncept för införandet av OBS. I studien 
ingår 72 patienter som opererades med tekniken mellan 2008 och 2010. Patienterna 
behandlades vid tre sjukhus i Danmark. Alla patienter delades in i fyra grupper 
beroende på hur stor tumören var och var i bröstet den satt. OBS inkluderar olika typer 
av tekniker. Vissa minskar storleken på bröstet (volyme reduction), andra flyttar på 
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bröstvävnad inom bröstet (volyme displacement) och slutligen finns tekniker som 
ersätter den bortopererade vävnaden med material som hämtas utanför bröstet (volyme 
replacement). Nästan ¾ av alla patienter blev också opererade i det andra bröstet för 
att förbättra symmetrin. Studien visade att den valda tekniken väl överensstämmer med 
den ideala grundat på vilken av de fyra grupperna patienten tillhör. Alla patienter blev 
förutom en opererad så som man planerat före operation. Den enda där det inte kunde 
genomföras var en patient där man var tvungen att ta bort hela bröstet för att säkert 
kunna få med hela tumören. Inget stöd fanns för att OBS, jämfört med tidigare studier, 
ökade antalet komplikationer eller ledde till en fördröjning av den efterföljande 
adjuvanta behandlingen. Sammantaget visade denna studie att det är möjligt att 
introducera ett standardiserat koncept för OBS, samt att OBS är ett kirurgiskt säkert 
koncept. 
I den andra studien presenteras en ny teknik inom OBS – en ”tunnelerad fasciokutan 
lambå med en hudö”. Tekniken innebär att vävnad från ryggen på patienten frias från 
underlaget och att man skapar en lambå, en vävnadssträng. Denna lambå träs sedan 
bakom huden och bröstet så att den når defekten i bröstet som skapas då man tar bort 
en tumör. Lambån består av både underhudsfett och hud och kan användas för att 
ersätta vävnad på ett annat ställe än där den ursprungligen satt. Det ingick 15 patienter 
i studien med antingen ”små” bröst (mindre än 250 ml) eller ”mellanstora” bröst (250-
500 ml). Dessa patienter hade hämtats från den grupp som ingick i den första studien 
och de hade opererats mellan 2008 och 2011. Ingen av patienterna behövde opereras 
på det andra bröstet eftersom tekniken eftersträvade att just ersätta vävnad som man 
var tvungen att ta bort och därmed kan man minska risken för skillnader mellan 
brösten. Alla operationerna kunde genomföras som planerat men efter slutlig 
bedömning av preparaten så behövde fyra patienter opereras igen eftersom tumören 
inte var avlägsnad med en tillräcklig marginal. Hos tre av patienterna opererades 
bröstvårtan bort och denna kunde ersättas med en hudö. Endast en patient fick en 
komplikation, en blödning. Sammantaget kan man betrakta denna OBS-teknik som 
genomförbar och säker.  
Syftet med den tredje studien är att jämföra onkologisk säkerhet för OBS jämfört med 
konventionell bröstbevarande kirurgi. Som nämnts ovan så är syftet med OBS att 
förbättra det funktionella och estetiska resultatet efter bröstcancerkirurgi. Det är 
emellertid mycket viktigt att säkerställa att den onkologiska säkerheten inte påverkas. 
Den onkologiska säkerheten kan mätas t.ex. genom att undersöka hur ofta kirurgin tar 
bort tillräckligt mycket vävnad för att man skall vara säker på att hela tumören är borta 
(radikal operation) eller genom att studera återfallsrisk. I denna studie ingick 197 
patienter opererade med OBS mellan 2008 och 2013 och det var en utvidgning av den 
grupp som analyserades i arbete ett och två. Dessa patienter hade i huvudsak opererats 
i södra Jylland. Denna grupp jämfördes med alla patienter i norra Jylland som opererats 
under samma tid, totalt 1399 patienter. Vi undersökte den onkologiska säkerheten 
genom att mäta fyra olika utfall. Det första var att undersöka om tumören var borttagen 
21 
med tillräcklig marginal, det andra var att se om den adjuvanta behandlingen 
(cytostatika eller strålning) fördröjts, det tredje måttet var återfallsrisk och det fjärde 
överlevnad. All data hämtades från den Danska Bröstcancergruppen (DBCG) vilken 
driver ett nationellt behandlingsregister. Studien visade att OBS-patienter hade relativt 
sett mer avancerade tumörer. Analyserna visade också att OBS-gruppen hade en mindre 
risk för en icke-radikal operation. Det sågs ingen skillnad mellan grupperna vad gällde 
tidpunkt för adjuvant behandling, återfallsrisk eller överlevnad. Sammantaget stöder 
studien antagandet att OBS är en onkologiskt säker teknik.  
Målet med OBS är att förbättra resultaten efter bröstbevarande kirurgi. Då är det ytterst 
väsentligt att undersöka hur patienterna själva upplever resultatet. Det fjärde arbetet 
undersöker om det finns skillnader i patientupplevt resultat mellan OBS-patienter och 
patienter opererade med konventionell bröstbevarandekirurgi. Studien undersökte de 
patienter som identifierats i studie tre. Det mätinstrument som användes var ett 
validerat frågeformulär: Breast-Q. Dessutom ingick en studiespecifik enkät. Totalt 
sändes formulären till 1504 patienter och det besvarades av 727 kvinnor. Analyserna 
visade att OBS-patienterna hade ett statistiskt säkert högre ”psykosocialt välmående” 
än jämförelsegruppen. Det sågs ingen skillnad mellan grupperna vad gällde 
”tillfredställelse med brösten” eller ”sexuellt välmående”. Vidare sågs det inte heller 
någon skillnad vad gällde ”fysiskt välmående”; detta även om OBS tekniken i många 
fall innebär större operativa ingrepp. Sammantaget stöder denna studie antagandet att 
OBS-kirurgi kan öka livskvalitén efter bröstkirurgi. 
Slutsatsen av avhandlingen är att OBS kan introduceras som en säker teknik vid 
behandling av bröstcancer och att den kan förbättra livskvalitén.  
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English summary  
Breast cancer is the most common cancer among women and accounts for about 25% 
of all female cancers in Denmark, and every ninth woman will be diagnosed with breast 
cancer during her life. Breast cancer is rare in young women, but the number of women 
with breast cancer increases with age with a maximum at 65-75 years of age. In 2016, 
around 4700 women in Denmark were diagnosed with breast cancer, and 87% of these 
will still be alive after five years. About 67000 women in the country are living after 
breast cancer treatment. Fortunately, the number of women diagnosed with breast 
cancer has decreased in the last decade. Since 2012 we have seen an annual decrease of 
about 1% of new patients diagnosed with breast cancer and an annual decrease in 
mortality of about 3.5%. The consequence of this development is that still more 
women will be alive after the diagnosis of breast cancer - and will live longer. This 
means, that the functional and aesthetic outcome of treatment becomes increasingly 
important. 
Surgical treatment of breast cancer is either mastectomy, where the breast is totally 
removed, or breast-conserving surgery (BCS), where only the tumour is removed. These 
two treatment options have the same documented effect on disease recurrence and 
survival. Today, about 70% of breast cancer patients are treated with BCS and up to 
30% of these patients may end up with an unacceptable functional and aesthetic result 
of surgery.  
With the aim of achieving better outcomes of the surgical treatment of breast cancer, 
oncoplastic breast surgery (OBS) has been developed in the last few decades. In OBS 
the techniques used in reconstructive and aesthetical plastic surgery have been applied 
to BCS. When these techniques are used in BCS it may be possible to reconstruct a 
larger number of breasts, after removal of the tumour, into normally shaped breasts 
with an acceptable functional and aesthetic result. Although, the implementation of 
OBS was initiated more than 10 years ago in Denmark, it has still not been fully 
implemented in all departments throughout the country. 
The aims of this thesis were to present a strategy for implementation of OBS in daily 
clinical practice in departments engaged in the surgical treatment of breast cancer, to 
evaluate the results of OBS with regard to feasibility of implementation, oncological 
safety of treatment, and to evaluate how breast cancer patients perceived satisfaction 
with treatment and quality of life after treatment. This thesis consists of four studies. 
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In the first study a strategy for implementation of OBS was presented. The study 
included 72 patients (74 tumours) operated with OBS in a collaboration between 
plastic and reconstructive surgeons and breast surgeons in the period 2008 to 2010. All 
patients were registered in a research database. Patients treated with OBS were selected 
from the wide population of all breast cancer patients. The patients were categorised 
into four groups depending on the size of the breast and the location of the tumour in 
the breast. The surgical techniques for reconstruction of the breast after removal of the 
tumour included techniques where the volume of the breast was reduced (volume 
reduction), where the breast tissue was rearranged within the breast after tumour 
removal (volume displacement), and where the defect in the breast after tumour 
removal was replaced by tissue recruited from outside the breast (volume replacement). 
Nearly ¾ of the patients also had an operation on the opposite breast to achieve 
symmetry. It was shown that the surgical technique chosen for reconstruction of the 
breast – the surgical strategy – depended on which of four groups the patient had been 
categorised into. In other words, we presented a strategy for how to choose the 
reconstruction technique in different cases of breast cancer selected for OBS. Surgery 
was performed as preoperatively planned on all 74 breasts except one, where it was not 
possible to remove the tumour without resection of the whole breast. We did not find 
an increase in complications of surgery or indications of delay of adjuvant therapy 
compared with BCS. In summary, this study indicated that implementation of OBS in 
daily clinical practice is feasible with the presented strategy without an increase in 
complications and without impairing the safety of the treatment with regard to timely 
administration of adjuvant therapy. 
In the second study we introduced a novel surgical technique using a tunnelled 
fasciocutaneous thoracodorsal flap with a skin island for immediate partial breast 
reconstruction in OBS. Using this flap, tissue is recruited from the thoracic wall and 
transposed through a tunnel in the breast, filling the defect after tumour resection. The 
flap is constituted of subcutaneous fat and skin and replaces both the volume removed 
by tumour resection and, if necessary, skin resected along with the tumour. This study 
included 15 patients, with small or medium-sized breasts, a subpopulation of the 
patients in the research database also used in the first study operated in the period 2008 
to 2011. Using this replacement technique none of the patients needed surgery in the 
other breast to achieve symmetry. All surgeries were performed as planned, although 
re-resection due to non-radical surgery was performed in four patients. In three patients 
the nipple areola complex (NAC) was removed along with the tumour and replaced 
with a skin island. There was only one complication to surgery, a haematoma at the site 
of reconstruction. In conclusion, we find this technique very useful and safe as an 
option in partial breast reconstruction in OBS. 
The aim of the third study was to evaluate the oncological safety of OBS compared 
with conventional BCS. As mentioned above, the aim of OBS is to improve the 
functional and aesthetic results of conventional BCS. However, it is very important to 
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document that oncological safety is not impaired by OBS. Only a few studies on this 
subject have previously been published comparing the oncological outcome of OBS 
with conventional BCS. In this study we identified 197 patients from the DBCG 
registry (a nationwide registry for breast cancer in Denmark) with newly diagnosed 
breast cancer treated with OBS that had been registered in the research database. These 
patients were compared with 1399 patients treated with conventional BCS, also 
identified in the DBCG registry, from another geographical region in Denmark, 
Region North. All patients were operated in the period 2008 to 2013. For evaluation 
of oncological safety we examined four items: non-radical tumour resection, delay in 
administration of adjuvant therapy (chemotherapy and radiotherapy), recurrent disease 
(disease-free-survival) and survival. Data for patient, tumour, and treatment 
characteristics were retrieved from the DBCG registry and the Danish Cause of Death 
registry for all patients. Data for OBS and conventional BCS, respectively, showed that 
patients treated with OBS had more advanced breast cancers than patients treated with 
conventional BCS. The results showed a lower risk for non-radical surgery for patients 
treated with OBS. We found no significant statistical differences with regard to time to 
administration of adjuvant therapy, disease-free-survival or survival. In conclusion, this 
study indicated that OBS is as oncologically safe as conventional BCS.  
As the aim of OBS is to improve the outcome of BCS it is important to document if 
the outcome of OBS, from the patient’s point of view, actually is an improvement. In 
the fourth study we evaluated the patient-reported outcome (PRO) of OBS compared 
with conventional BCS. For evaluation the validated questionnaire Breast-QTM BCT 
module and a study-specific questionnaire (SSQ) were used. In 2016, the same patients 
from the OBS research database and from Region North, who were included in the 
third study (1504 patients in all), were sent the questionnaires either by E-post (a secure 
public digital platform) or by ordinary mail. Ninety-six replies were received from OBS 
patients and 631 replies from patients treated with conventional BCS, 727 replies in 
all. The results showed a statistically significant better outcome of “Psychosocial Well-
being” for patients treated with OBS compared with conventional BCS. No statistical 
differences were shown for “Satisfaction with Breast” or “Sexual Well-being”. 
Furthermore, no differences were shown for “Physical Well-being”, despite more 
comprehensive surgery for patients treated with OBS, where surgery of both breasts 
was often performed to achieve better symmetry. In conclusion, the results of this study 
indicated better PRO for OBS concerning psychosocial well-being. 
In summary, the results of the studies in this thesis showed that implementation of 
OBS in daily clinical practice is feasible without compromising the oncological safety 
of the treatment of breast cancer, and indicate that OBS improves the PRO compared 
with conventional BCS. 
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Introduction  
The subject of this thesis is oncoplastic breast surgery (OBS). In brief, OBS is a discipline 
in which techniques known from reconstructive and aesthetical plastic surgery are applied 
to breast conserving surgery (BCS) in an effort to achieve better functional and aesthetical 
outcomes in the surgical treatment of primary breast cancer 1-3.  
The motivation for the studies included in the thesis arose from the daily clinical work 
at the Department of Surgery, Hospital of South Jutland, Denmark, in the Plastic 
Surgery and Breast Surgery sections. At the Department of Surgery, we, as plastic 
surgeons, work closely with the breast surgeons. Formerly, this the cooperation was 
limited to surgery for congenital defects such as tuberous breast or aplasia of the breasts, 
and total reconstruction after mastectomy, either as primary or secondary 
reconstruction, while treatment of primary breast cancer with BCS or mastectomy was 
performed solely by breast surgeons. Inspired by the early research results presented at 
conferences and in literature – especially the work of McCulley and MacMillan 4, 5 - 
combined with our experience with the results of BCS, we saw a potential for improving 
the surgical outcome of surgery for breast cancer for our patients. The experience was 
that BCS in many cases led to poor results for our patients - in the literature up to 30% 
6, 7. 
As a result of this we agreed to develop a strategy for implementation of OBS in the 
daily clinical practice for treatment of breast cancer patients. The goal was to develop a 
surgical strategy and a setup in the clinic to include the broad spectrum of breast cancer 
patients that receive surgical treatment at the department. This meant that we had to 
schedule consultations where breast surgeons and plastic surgeons were able to see 
possible candidates for OBS. After referral to the breast unit all patients were first seen 
in a consultation with the breast surgeon. When the breast surgeon´s judgement was 
that a patient would not have an acceptable outcome of BCS, a common consultation 
was scheduled the same day or within a few days – very often on an ad hoc basis as time 
is short in the treatment of breast cancer.  
The result of this setup was that we as plastic surgeons were presented with very 
different cases with very different reconstructive problems. Breasts vary in size from 
small to large, as do tumours, and the tumours can be located anywhere in the breast – 
and can even be multifocal or bilateral. In the effort to solve these different 
reconstructive tasks we had to include our experience with a wide range of techniques 
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from reconstructive and aesthetical breast surgery. If we concluded that OBS was a 
feasible option, and the patient accepted the plan for surgery, surgery was scheduled 
and carried out with both a breast surgeon and a plastic surgeon working together as a 
team. Although surgery was performed by both breast and plastic surgeons in the same 
surgical procedure, we had a clear agreement on responsibilities – the breast surgeon 
was responsible for the oncological surgery while the plastic surgeon was responsible for 
the reconstructive surgery. Through the first years we learned a lot – both breast and 
plastic surgeons – and the strategy developed as a result of this experience. This meant 
that we included more patients and more difficult cases, as well as patients who 
otherwise would have been recommended for mastectomy, and new surgical techniques 
were included and improved. Over time, the breast surgeons took decisions on and 
performed minor reconstructive procedures themselves, while we as plastic surgeons 
participated in reconstructions when needed. 
Although it was our opinion that our approach to OBS worked and our results were 
promising with regard to aesthetical and functional outcome after the first years, it was 
obvious that two very important issues had to be evaluated. The first issue, and the 
most important one, was whether OBS led to impairment of the oncological safety of 
treatment of breast cancer compared with conventional BCS. The second issue was how 
the patients perceived the results of the treatment: did they benefit from the more 
extensive surgery and how did that influence their HRQoL? 
The aims of the studies included in the thesis are to present a strategy or a guideline, 
which could possibly inspire other clinicians to implement OBS in daily clinical 
practice and as a second aim, to present a novel surgical technique using a tunnelled 
fasciocutaneous thoracodorsal flap with a skin island, as a supplementary tool for 
reconstruction of defects after partial mastectomy. Furthermore, it was very important 
to evaluate the oncological and HRQoL outcomes of OBS compared with conventional 
BCS. 
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Breast cancer 
Epidemiology 
Breast cancer is the most frequently occurring cancer among woman in Denmark. 
Every ninth woman will be diagnosed with breast cancer during her life span, and breast 
cancer accounts for 25% of all female cancers 8.  
The incidence of breast cancer in Denmark, i.e. new cases per year, increased until 
approximately 2010, when a fall was registered, and the incidence has continued to fall 
since then 9. In 2016, the incidence in Denmark was 4694 (mean for the period 2012-
2016). The incidence of breast cancer is strongly correlated to age. Breast cancer is rare 
before the age of 30 years in Denmark. The incidence reaches its maximum at the age 
of 65-75 years and declines gradually to the age of 85+ years. Over the last 10 years 
there has been an estimated annual age-standardised change per year in incidence of 
minus 1.1% 9. 
In 2016, 1120 women in Denmark died per year due to breast cancer (total mortality 
as a mean for the period 2012-2016) and the estimated age-standardised annual change 
was minus 3.4% 9. In 2012 to 2016 the one-year relative survival (%), i.e. the 
probability of patient survival in the absence of other causes of death, was 97% (CI 
95%; 96−97) and the five-year relative survival was 87% (CI 95%; 86−88). The 
prevalence of breast cancer in Denmark, i.e. women living with the breast cancer 
diagnosis, was 66300 in 2016. The consequence of these figures is that the prevalence 
of breast cancer in Denmark at present is increasing 9. 
Diagnosis 
The diagnosis of breast cancer in Denmark is based upon three items, according to the 
national guidelines provided by DBCG, called the “Triple-diagnostic principle”: 
clinical examination, diagnostic imaging (e.g. mammography and ultrasound) and 
cytological and histological examination of tissue samples 10.  
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Suspicion of breast cancer occurs mainly either because of clinical symptoms, such as 
detection of a palpable tumour in the breast, retraction of the nipple or skin, secretion 
of fluid or blood from the nipple, or as a result of screening mammography. When a 
suspicion has been raised the patient is then referred, usually by a general practitioner, 
to a breast unit or to a department of radiology for a clinical mammography 10.  
When a breast cancer diagnosis is established, the decision on the treatment 
recommendation of the individual patient, based on the results of the triple-diagnostic 
procedure, is taken at the Multi Disciplinary Team (MDT) conference, according to 
national guidelines 11. Specialists in breast surgery, pathology, oncology and radiology 
participate in the MDT team.  
Prognostic factors 
Age and menopausal status 
The prognosis of breast cancer is correlated to age at diagnosis 12. Patients diagnosed 
with breast cancer when aged under 40 and more than 80 years have a poorer prognosis 
than patients when aged between 40 to 80 years. It is well known that menopausal 
status is closely associated with age, and as such, is also covariate with prognosis 13.  
Multifocality 
Most breast cancers are uni-focal tumours but some tumours are multifocal or 
multicentric 14. Multifocal tumours are defined as those with more than one focus of 
invasive tumours separated by carcinoma in situ or normal breast tissue in the same 
quadrant, whereas multicentric tumours have two or more focuses in more than one 
quadrant. Multicentricity are associated with an increased risk of metastases, which 
indicates a poor prognosis 14, 15 . 
Vascular invasion 
Invasion of tumour cells in blood vessels is seen as tumour growth progresses in breast 
cancer. Vascular invasion is documented to be a prognostic factor as vascular invasion 
predicts a poorer prognosis 16.  
Histopathology  
Invasive breast cancer is defined as malignant tumours cells penetrating the basal 
membrane originating from the ducts or lobules in the mammary gland. With 75-80% 
the invasive ductal carcinoma, or invasive ductal carcinoma of no special type (NST), 
is the most common histological type followed by invasive lobular carcinoma with 
approximately 10-15% 10, 17 . Mucinous, tubular and medullary tumours represent 
approximately 5%. The prognosis of breast cancer is associated with histopathology of 
the tumour, where invasive ductal cancers have a better prognosis compared with 
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lobular cancers 18. Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ 
represent another histopathological type of breast tumour. These tumours are non-
invasive but might develop into invasive carcinomas 19, 20. The prognoses of DCIS 
tumours are indexed according to the Van Nuys Prognostic Index, based on tumour 
size, margin width and pathological classification from 1 – 9. A high index corresponds 
to a higher recurrence rate. 
Histological grade 
During the study, breast tumours were classified according to The Nottingham 
Histological Grade (NHG) system 21, 22. The grading is based on microscopic examination 
of tissue samples, where tubule formation, nuclear pleomorphism and mitotic activity are 
graded and expressed as a sum as NHG 1 to NHG 3. A high NHG grade corresponds to 
lower differentiation and is associated with a poorer prognosis 18, 23. 
Biomarkers 
Immunohistochemical (IHC) analysis for estrogen receptors (ER) and progesterone 
receptors (PgR) is routinely performed 10. Approximately 80% of the tumours are ER-
positive (> 1% of the cells in the tumours have the receptor in the cell nucleus) and ER 
is a strong predictive factor in breast cancer and can be targeted by hormone therapy 
24. ER- and PrG-positive tumours are predictors for a long-lasting effect of hormone 
therapy 25. Human epidermal growth factor receptor 2 (HER2) is a tyrosin kinase 
receptor located in the cell membrane and can be overexpressed in breast cancer, i.e. 
HER2 positive, which is found in approximately 20 % of tumours 10. HER2-positive 
tumours are associated with poorer prognosis and will benefit from immunotherapy 
(trastuzumab), hence HER2 is a strong prognostic and predictive factor 26. Also, 
analysis for the human epidermal growth factor (HER2) is routinely performed (with 
IHC and FISH). The biomarker Ki-67 is a marker for the speed of cell divisions and 
cell proliferation, and is a prognostic but not a predictive factor as high levels of Ki67 
are associated with poorer prognosis 27. Data for ER, PgR and HER2 are included in 
the DBCG registry for the study period and in the studies in this thesis. The Ki-67 
index was not included in the DBCG registry throughout the entire study period and 
due to this it was not included in the studies. 
TNM-classification 
The TNM-classification system is an international recognised one in which the cancer 
is staged with regard to the size of the tumour, nodal involvement and metastases 22. 
The TNM staging is strongly correlated to the prognosis of breast cancer, where a 
higher stage indicates a poorer prognosis for the individual patient, and it is used when 
deciding on the recommended treatment 18, 28.  
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Treatment of breast cancer 
The DBCG provides national guidelines for the treatment of breast cancer in Denmark, 
and these guidelines are followed by all certified departments involved 10. 
Surgery 
Recommended surgical treatment depends on stage, the tumour size and location, and 
the breast size as well as a broader evaluation of the patient with regard to age and 
comorbidity.  
Sentinel node surgery 
A sentinel node biopsy (SNB) is nearly always performed as a part of the staging of 
breast cancer 10. The SNB is usually performed as the first part of the surgical procedure, 
but can be performed as an independent procedure prior to BCS or mastectomy, e.g. 
if a primary autologous total reconstruction is planned. The SNB was during the study 
period examined by frozen sections. In the case of malignant cells in the SN, i.e. a 
positive SN, an axillary clearance was also performed within the same surgical 
procedure. If no malignancy was found, i.e. a negative SN, no further surgery was 
performed 10. A positive SN is correlated to a poorer prognosis 29. 
Axillary lymph node dissection 
Axillary lymph node dissection (ALND), i.e. surgical removal of the axillary lymph 
nodes, was recommended during the period when metastases to axillary lymph nodes 
were diagnosed 10. The purpose of axillary dissection is staging and regional disease 
control. Metastases to the axillary lymph nodes can be diagnosed by SNB either as 
micro- (0.2 - 2 mm), macro-metastases (>2 mm) or cell clusters (ITC, isolated tumour 
cells <0.2 mm), or by other diagnostic tools such as PET-CT scans, MR scans, ultra-
sound, excision or needle biopsies and even clinical examination. In 2019 ALND was 
only performed when macro-metastases were diagnosed by SNB10. Axillary dissection 
is usually performed in the same surgical procedure as BCS or mastectomy. However, 
axillary dissection can be performed later in cases of late positive SNB, diagnosed in the 
final histopathological examination. Surgery is usually performed through a separate 
incision in the axilla, i.e. a different incision than the incision for partial mastectomy 
or mastectomy. According to the national guidelines by DBCG in Denmark, an axillary 
dissection ought to include at least 10 lymph nodes10. 
Mastectomy 
Mastectomy is the surgical procedure where the whole mammary gland is removed 30. 
In Denmark approximately 30% of patients with breast cancer were treated with 
mastectomy in 2016 10. Mastectomy is recommended in cases where it can be foreseen 
that the outcome after BCS will leave the patient with an unacceptable aesthetical 
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outcome. This can be the scenario when the tumour is large, multifocal or located in 
an unfortunate position with regard to BCS. Mastectomy is also recommended in cases 
with recurrent local disease and in most cases with local advanced disease with 
involvement of the skin. Mastectomy can be performed in a procedure where the 
mammary gland along with an appropriate amount of skin is resected for adaption to 
the thoracic wall for closure or as a subcutaneous mastectomy 31 where the skin 
overlying the mammary gland is preserved.  
Conventional breast-conserving surgery 
In breast-conserving surgery the tumour is removed by a partial mastectomy, with the 
intention of not leaving any cancer cells in the breast. BCS can be performed if an 
acceptable functional and aesthetic outcome is anticipated – and accepted by the 
patient. In Denmark approximately 70 % of patients (2016) with breast cancer are 
operated with BCS 10. In BCS it is essential that the tumour is removed with free 
margins. During the study period (2008-2013) a radical excision was defined as ≥ 2 
mm from carcinoma to excision line for both invasive and carcinoma in situ. Since 
2013 “no tumour on ink”, i.e. no tumour cells at the resection surface coloured by ink 
at the final histopathological examination, is accepted as demonstrating free margins 10, 
32. Whether the resection margin is sufficient is determined peroperatively by the 
pathologist by macroscopic examination. If the microscopical examination with frozen 
section peroperative shows that the resection margins are too narrow, an immediate re-
resection is performed. The ensuing defect in the breast after the resection is then closed 
by suture with no further adaption of the breast. A final histopathological examination 
is always performed. In cases where this examination shows tumour cells at the resection 
margin, i.e. there is a positive margin, a secondary re-resection or a mastectomy is 
recommended 10.  
Breast reconstruction 
Breast reconstruction is the surgical reconstruction of the breast after either complete 
or partial mastectomy. Breast reconstruction can be performed as an immediate or 
delayed procedure, and with regard to surgical techniques, with the use of implants or 
by transfer of autologous tissue to the breast - or combinations of implant and tissue 
transfer.  
An immediate reconstruction is performed in the same surgical procedure as the 
mastectomy or BCS, while a delayed reconstruction is performed in a later surgical 
procedure. Breast reconstruction after mastectomy can be performed as either an 
immediate or delayed procedure. Breast reconstruction after partial mastectomy is 
performed as an immediate procedure.  
In autologous total reconstructions the breast is reconstructed using tissue flaps 
transferred from outside the breast. The flap most often used for breast reconstruction 
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is the deep inferior epigastric perforator flap (DIEP) flap, recruited from the abdomen, 
which is transferred to the breast with a microsurgical technique 33. With the use of this 
flap it is possible to recruit enough tissue to reconstruct the breast without the use of 
an implant. Another flap for breast reconstruction is the muscle-sparing latissimus dorsi 
flap (ms-LD flap), which is a pedicled flap harvested from the back 34. Reconstruction 
with ms-LD flaps is usually combined with an implant as it is not possible to recruit 
enough tissue to reconstruct the breast volume with the flap alone. In cases where 
patients have had adjuvant radiotherapy autologous reconstructions are highly 
preferred due to fibrosis caused by radiation 35.  
Partial immediate autologous breast reconstruction, i.e. OBS, is reconstruction of the 
breast when a partial defect in the breast caused by partial mastectomy is present. The 
reconstruction is carried out by the use of internal tissue transfer, e.g. tissue recruited 
from inside the breast, or by the use of external tissue transfer by local flaps from outside 
the breast.  
Reconstructions with implants are either one- or two-stage reconstructions. In an 
immediate reconstruction the mastectomy may be performed as a subcutaneous 
mastectomy 31, with or without resection of the NAC, immediately followed by a 
reconstruction with an implant, usually placed under the pectoral muscle 36. In a 
delayed reconstruction either a one- or a two-stage procedure is needed. Delayed one-
stage breast reconstruction is performed by implantation of an expandable implant 
designed for one-stage reconstruction 37. In a two-stage reconstruction an expandable 
implant is implanted, which, after expansion of the overlying tissue over several weeks, 
is replaced in a second surgical procedure by a permanent implant 38. Delayed total 
reconstruction with an implant is not recommended when the patient has had adjuvant 
radiotherapy due to the increased risk of fibrosis with capsular contracture 35.  
As a new technique for breast reconstruction, autologous fat transplantation (AFT), has 
been developed. This is a tool for corrections of sequelae after oncological or 
reconstructive surgery and even for total breast reconstructions 39-41. 
Reconstruction of the NAC is often performed as the final part of the breast 
reconstruction. Several techniques for reconstruction of the nipple as well as the areola 
are available 42-44. 
Adjuvant therapy 
Adjuvant therapy includes several modalities: radiotherapy, chemotherapy, hormonal 
therapy and immunotherapy. Specific treatment guidelines are provided by DBCG for 
all modalities and are continuously updated 10. In selected cases with large or multifocal 
tumours, and HER2 positive or high grade tumours, neoadjuvant chemotherapy is 
recommended for down-staging of the tumour prior to surgery 8, 10. Whether 
35 
postoperative adjuvant chemotherapy is indicated depends on the results of 
histopathology examination, TNM-classification and analysis of biomarkers, age and 
comorbidity independently of the surgical treatment (BCS or mastectomy). Patients 
treated with BCS are recommended to undergo postoperative adjuvant radiotherapy in 
all cases regardless of the results of these parameters. Only patients who have had a 
mastectomy with macro-metastases in regional lymph nodes, with tumours > 5 cm or 
non-radical surgery, are recommended to have postoperative adjuvant radiotherapy 10. 
The indication of treatment with hormonal therapy and immunotherapy depends on 
the analysis of the biomarkers ER and HER2 according to the national guidelines 10.  
Follow-up 
Patients are scheduled for follow-up according to the Danish national guidelines 10. 
Follow-up visits at department of oncology or breast surgery were usually planned for 
every three months during the first year postoperatively, every sixth months from two 
to five years, and once every year from six to ten years postoperatively. Patients treated 
with BCS (including OBS) are recommended to have a mammography 18 months 
postoperatively. After this first postoperative mammography patients are referred to the 
screening programme, having a mammography every second year. Later events such as 
recurrence of disease either as local or disseminated disease, a second contra lateral 
breast cancer or death are registered in the DBCG registry 10. 
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Oncoplastic Breast Surgery 
In reconstructive plastic surgery, the main task is to repair defects of various kinds. These 
may be congenital, such as cleft lip and palate defects, or acquired following trauma or 
ablative surgery. One such example is surgery to the breast due to cancer. The goal of 
reconstruction is then to restore function with the best possible aesthetic outcome. From 
a plastic surgical point of view the defect caused by partial mastectomy is a classical 
reconstructive problem. Partial mastectomy leaves the breast with a defect and a problem 
to solve: how to restore the breast with an acceptable aesthetic and functional outcome. 
In OBS, resection of the tumour is immediately followed by reconstruction of the 
breast. The goal of this combined procedure is to achieve local control of the disease 
and at the same time an acceptable aesthetic and functional outcome. Studies have 
shown that these goals are achieved in the short term 3, 4, 7, 45, 46 although studies on long-
term outcomes are few 47, 48. The surgical strategy chosen for the individual patient 
depends on the size and location of the tumour in the breast, the size of the breast, and 
possible donor sites 2, 46. Furthermore, the patient’s acceptance of the preoperative plan 
including possible surgery to the contralateral breast to achieve better symmetry has to 
be obtained. The patient also has to be informed of the possibility of mastectomy in 
case it is not possible to achieve free margins with a partial mastectomy.  
With this approach to breast-conserving surgery, OBS has evolved in the last few 
decades. OBS applies techniques from reconstructive and aesthetic plastic surgery to 
conventional BCS with the aim of improving the outcome of BCS. With this evolution 
the indications for BCS have also expanded with the result that more women with 
breast cancer can avoid mastectomy and still achieve an acceptable aesthetical and 
functional outcome 49, 50. 
The reconstructive problem to solve – if possible - is determined by several factors. The 
volume and shape of the breast(s) are not equal from woman to woman, but vary widely 
from small breasts to very large breasts. Furthermore, the breasts are not always 
symmetrical. The size of tumours varies from patient to patient within a range of a few 
mms to several cm in diameter. The shape can be round or highly irregular, the tumours 
can be unifocal or multifocal, and can be located anywhere in the mammary gland. 
Regardless of these factors, the essential goal for BCS is to achieve radical resection of 
the tumour within acceptable margins, according to national guidelines, to provide the 
safest possible oncological outcome.  
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This means that the location and relative size of the defect, after resection of the 
tumour, varies from woman to woman, leaving very different reconstructive problems 
to be solved taking the remaining breast into consideration 5, 51. This can be illustrated 
by the differences in the problems between cases where, for example, a small tumour is 
located in the lower part of a large breast compared to a case where a tumour of the 
same absolute size is located in the upper lateral part of a small breast. This calls for 
different reconstructive approaches and techniques to achieve acceptable aesthetic and 
functional outcomes. The first case could be operated with a reduction mammoplasty, 
possibly in combination with a contralateral mastopexy to achieve symmetry 4. The 
second case could be reconstructed with a replacement technique with use of a 
perforator flap from the thoracic wall, thus leaving no need for contralateral surgery 52, 
53. However, not all defects after radical tumour resection are possible to reconstruct 
with an acceptable outcome. In these cases, mastectomy and maybe immediate or 
delayed total breast reconstruction with implants or autologous tissue are still the best 
options for surgical treatment 33, 34, 36, 38.  
Definition of OBS 
Over the last few decades several different approaches to OBS have been described 
involving a number of surgical techniques for reconstruction of various defects in the 
breast leading to different concepts for implementation of OBS in breast cancer surgery 
2, 4, 46, 54-56. 
Different definitions of OBS have been introduced but so far there has been no 
agreement on a common international definition of OBS. Recently Chatterjee et al. 
published the American Society of Breast Surgeons’ consensus definition and 
classification system of OBS 1. Their definition and classification is widely inspired by 
the work of Clough et al. 2, 51. Chatterjee et al. define OBS as ”A form of breast 
conservation surgery that includes oncologic resection with a partial mastectomy, 
ipsilateral reconstruction using volume displacement, or volume replacement 
techniques with possible contralateral symmetry surgery when appropriate” 1 . 
Chatterjee et al. also propose a classification system in which they classify OBS at levels 
I and II based on the needed resection volume as a percentage of the total breast volume 
1. Furthermore, they include the surgical skills and techniques required for levels I and 
level II in the categorisation. When up to 20% of the total breast volume has to be 
resected to achieve free margins, level I OBS is usually sufficient. The techniques used 
in level I OBS are, in their classification system, local tissue rearrangement, mastopexy 
and doughnut mastopexy. Level I OBS can be performed by most breast surgeons 
without experience of reconstructive techniques 1, 2. When the partial mastectomy 
constitutes 20 – 50% of total breast volume they classify OBS as level II. The proposed 
technique for partial immediate reconstruction in level II is reduction mammoplasty, 
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possibly including a free nipple graft and circum vertical mastopexy. A third category 
called “Volume replacement” is proposed when the partial mastectomy includes more 
than 50% of the total breast volume. For possible reconstructive techniques in this 
scenario, local and regional flap reconstruction such as thoracodorsal artery perforator 
flaps (TAP flaps) are listed as well as implant-based reconstructions. Level II requires 
experience with reconstructive techniques from plastic surgery 1. 
However, the proposed cut-offs in volume at 20% for level I surgery and 50% for level 
II surgery, and the corresponding surgical techniques recommended, should not be 
regarded as hard cut-offs. The definition and categorisation rather have to be regarded 
as guidelines 1. The specific reconstruction option that is chosen for the individual 
patient depends on the size of the breast, the size and location of the tumour – and the 
patient`s wishes.  
In this thesis we have defined OBS levels I and II as described below.  
Surgical strategies in OBS 
Level I OBS 
The surgical techniques used in level I OBS include simple partial mastectomy, possibly 
with expanded skin incision lines, and closure of the ensuing defect by minor 
mobilisation of adjacent skin, subcutaneous and mammary tissue with or without 
recentralisation of the NAC. Examples of these techniques are donut 57, 58, racket 59 and 
batwing 60 techniques. These techniques are most often used in cases where the defect 
after partial mastectomy in relation to the remaining breast is small (<20%) 1 . 
Furthermore, the tumour has to be located in a suitable position in the breast. Surgery 
for level I OBS can be performed by most breast surgeons and does not require skills 
or experience from reconstructive or aesthetical plastic surgery.  
Level II OBS 
Surgery for level II OBS includes three main categories of surgical techniques: the 
volume reduction technique or therapeutic mammoplasty 4, displacement techniques5 
and replacement techniques 34, 52, 61, 62. These surgical techniques all require acquired 
surgical skills and experience with methods used in reconstructive and aesthetical plastic 
surgery as they include techniques used in breast reduction surgery, mastopexy and flap 
procedures. Patients operated with mastectomy followed by an immediate autologous 
or implant reconstruction were not included in our definition of level II. 
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Volume reduction techniques 
For women with large or even medium-sized breasts, volume reduction for immediate 
reconstruction is an easy and safe technique 4, 5. The technique is applicable in patients 
where the size of the breast and the location of the tumour allow a reduction 
mammoplasty including the tumour, leaving a sufficient amount of breast tissue to 
reshape the breast after tumour removal, i.e. a therapeutic mammoplasty 4. Different 
surgical techniques for reduction mammoplasties exist 63. The volume reduction 
technique is typically, but not all ways, used in cases where the tumour is located in the 
lower part of the breast within the limits of the incision lines used for breast reduction 
5. Patients with breast cancer operated with the volume reduction technique will have 
a smaller, but naturally shaped breast. If needed, reduction mammoplasty of the 
contralateral breast to achieve appropriate symmetry may be performed.  
Volume displacement techniques 
The principle used in the displacement technique is to fill the defect after resection of 
the tumour, i.e. after partial mastectomy, wherever it is located in the breast, with breast 
tissue recruited from within the breast 5, 64, 65 . The use of displacement techniques also 
implies that the volume of the breast is large enough to allow a reduction of the breast 
that equals, at a minimum, the volume of the partial mastectomy. An example of 
reconstruction with displacement technique is reconstruction of a central defect 
following resection of a tumour including the NAC using a flap from the lower part of 
the breast. The NAC can be reconstructed as an immediate reconstruction using a flap 
with a skin island 42, 44, 53. There are numerous ways of designing immediate 
reconstruction with displacement techniques depending on the surgeon´s skills and 
experience 5, 51. How to design the reconstruction depends on the size of the breast and 
the location and size of the ensuing defect after tumour resection. These reconstructions 
include wide skin incisions, mobilisation of breast tissue and often flap surgery with 
random flaps. These reconstructions are used with medium to large breasts. As these 
techniques also result in a smaller breast than preoperatively, a contralateral reduction 
mammoplasty is usually performed in the same procedure to achieve symmetry. 
Volume replacement techniques 
For women with small breasts, conventional BCS usually leads to a considerable and 
mutilating deformity of the breast, which adjuvant radiation therapy might further 
aggravate 48, 66. The relation between the size of the breast and the tumour in women 
with small breasts also means that it is not possible to reconstruct the breast after 
tumour resection using volume reduction or volume displacement techniques with an 
acceptable aesthetic outcome. To reconstruct such defects, it is necessary to replace 
volume with external flaps, i.e. to recruit tissue from outside the breast to fill the defect. 
Different flaps for this purpose are available depending on the location and the volume 
of the defect. For smaller defects, random flaps 53, 62 or perforator flaps 52, e.g. ICAP-
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flaps 67 or TAP flaps 68, with or without skin are often suitable. When more tissue is 
needed for the larger defects, the muscle sparing ms-LD flap may be a versatile option 
34. Also, in these reconstructions using flaps the NAC can be reconstructed if needed in 
the same surgical procedure 42, 44. The replacement technique can also be used for 
women with medium-sized breasts, who do not consent to an operation on the 
contralateral breast to achieve better symmetry.  
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Oncological outcomes of the treatment 
of breast cancer 
To evaluate if the oncological outcomes of OBS compared with conventional BCS, 
primary radical excision and timing of adjuvant therapy were chosen as the first two 
endpoints. The outcome of these two endpoints could affect the outcome of disease-
free survival, the third end-point, and survival, the fourth end-point, which are the 
most essential outcomes. It is reasonable to assume that the evaluation of these 
endpoints can give a fair indication of the oncological safety of OBS compared with 
conventional BCS. 
Primary radical excision 
Radical excision is essential in the surgical treatment of breast cancer. In consequence, 
a non-radical primary excision has to be followed by secondary surgery with re-excision 
to achieve free margins according to the national guidelines. In our study, radical 
excision was defined as ≥ 2 mm from invasive carcinoma to excision line and ≥ 2 mm 
from ductal carcinoma in situ if ductal carcinoma in situ was also present. However, 
during the last six months of the study period “no tumour on ink” was accepted as 
demonstrating free margins for invasive carcinoma and remains so 10. 
In cases where the size of the tumour in relation to the size of the breast is small, tumour 
excision can often be performed with sufficient margins without applying oncoplastic 
techniques 1, 2, 51. However, in breasts where the size of the tumour in relation to the 
size of the breast is large, tumour excision may compromise the aesthetic outcome 4, 46, 
66, 69. This is also true in cases where a small tumour is, for instance, located in an upper 
medial quadrant of the breast. In these cases, even when OBS is used, the reconstruction 
is still technically challenging. With this in mind, one could argue that the surgeons 
performing OBS could have a tendency to compromise the radicality of the tumour 
excision by minimising the excision margins in an effort to get the best possible result 
regarding aesthetical and functional outcome. Because of this it is substantially to 
evaluate the outcome of OBS compared with conventional BCS with regard to primary 
radical excisions. 
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Timing of adjuvant therapy 
It is generally agreed that, to have the best effect, adjuvant chemotherapy ought to be 
initiated within a maximum of 12 weeks after surgery 70-72. Other results have confirmed 
that this is true for radiotherapy as well 73. Furthermore, studies show that the time to 
initiation of adjuvant chemo- and radiotherapy has an impact on disease-free survival 
and survival 71-73. 
OBS includes more extensive surgical procedures than conventional BCS and in some 
patients even contralateral surgery to achieve better symmetry. More extensive surgery 
can lead to an increase in the rate of complications. Due to this fact, it is a concern that 
complications, e.g. haematomas, infections, delayed wound healing and necrosis of 
flaps, could be a reason for delay of adjuvant therapy in OBS as administration of 
radiotherapy as well as chemotherapy requires a well healed breast 69, 74.  
In this study we regarded administration of the first mode of adjuvant therapy as 
delayed if initiated after more than four weeks. In our study III we investigated whether 
there were any statistically significant differences in time to initiating administration of 
adjuvant therapy comparing OBS with conventional BCS. 
Disease-free survival 
Disease-free survival, i.e. survival with absence of recurrent disease, has improved over 
the last decades as a result of screening mammography, better surgery and the 
development of adjuvant therapy 10. The oncological safety of conventional BCS has 
proved to be as high as that of mastectomy 75, 76. To evaluate the oncological outcome 
of OBS compared with conventional BCS, we consider evaluation of disease-free 
survival important. Data for recurrent disease was retrieved from the DBCG registry.  
Survival 
A decrease in mortality following treatment of breast cancer has also been reported in 
the few last decades 9. To evaluate the oncological outcome of OBS compared with 
conventional BCS mortality is an essential subject. In our study, we evaluate mortality 
expressed in terms of cancer as the underlying cause of death, breast cancer as the 
underlying or multiple cause of death, and overall cause of death.  
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Patient-reported outcome 
Previous evaluations of surgical treatment, including breast surgery, have mainly 
focused on clinical outcomes such as duration of hospital stay, number of surgical 
complications, e.g. haematomas, wound healing, infections etc., evaluation of 
postoperative pain, and, of course, cancer recurrence and mortality, but these clinical 
outcomes can no longer stand alone 77, 78. Studies of functional and aesthetic outcomes 
in reconstructive and especially aesthetical breast surgery have also been performed to 
get an indication of patient satisfaction with the results of treatment 47, 79-82.  
During the last few decades an increasing interest in measuring and evaluating the 
patient perception of results of treatment, i.e. PRO, has evolved with a focus on 
satisfaction and HRQoL 83. This is true for aesthetical and reconstructive breast surgery, 
but this also applies to services in other specialities, e.g. bariatric and body-contouring 
surgery after massive weight loss 84, 85. PROM data is increasingly used in decision-
making in healthcare. Data is used with regard to treatment of the individual patient, 
in research and healthcare policy, and makes it important that PROMs provide 
scientifically sound measurements 77, 86, 87. The use of PROMs that are not properly 
developed or validated could lead to use of data that do not reflect reality, i.e. that are 
imprecise or biased, and this can lead to undesirable decisions and strategies for clinical 
practice 88. 
For the measurement of PRO in OBS we chose the Breast-Q BCT postoperative 
module 83 . 
Breast-Q™ - a Patient-Reported Outcome Measure 
(PROM)  
The Breast-Q™ is a disease-specific validated questionnaire for evaluating PRO 
developed by the Memorial Sloan Kettering Cancer Institute, New York, USA, and the 
University of British Columbia, Toronto, Canada 77, 78, 89, 90. 
The Breast-Q is a part of the q-portfolio 83. The Breast-QTM questionnaires, at present 
including five modules (augmentation, reduction, reconstruction, BCT and 
mastectomy), have been developed based on literature reviews, patient interviews, focus 
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groups and expert panels 89. The questionnaires were tested and re-tested among 
patients and scales (scoring) constructed by use of Rasch measurement methods and 
psychometric analysis 90. The linguistically validated Danish version of the Breast-QTM 
BCT postoperative module (2016) includes 10 domains. The domains represent two 
overall categories: satisfaction and HRQoL 89. Each domain can be used independently 
of the other domains. Four domains concern the patient-reported outcome of 
treatment, “Satisfaction with breast”, “Psychosocial Well-Being”, “Sexual Well-Being” 
and “Physical Well-Being”, and four domains concern satisfaction with the breast 
surgeon and oncologist and their information prior to treatment. Finally, two domains 
regarding satisfaction with medical staff other than the breast surgeon are included. 
Each domain, or subscale, consists of a varying number of items. Permission to use the 
Danish version of the Breast-Q BCT postoperative module was granted by the MAPI 
Research Trust Institute 91 . Data from the Breast-Q™ BCT postoperative module was 
transformed into scores ranging from 0 to 100 for each domain according to the 
guidelines for the Breast-Q BCT postoperative module with higher scores representing 
more favourable outcomes. 
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Aims 
The overall aim of the studies is to present a strategy for implementation of OBS and 
to evaluate the strategy with regard to feasibility, oncological safety and patient-
reported outcome.  
The specific aims for the studies were: 
Paper I: To present and evaluate a possible strategy in the planning of OBS in terms of 
different reconstruction methods related to tumour size, tumour location and size of 
the breast. The result of surgical radicality, surgery due to insufficient resection margins, 
late positive sentinel nodes and early postoperative complications was also evaluated. 
Paper II: To introduce and evaluate a novel technique, using a tunnelled lateral 
fasciocutaneous flap with a skin island, for use in OBS when tissue replacement is 
indicated.  
Paper III: To investigate if there are differences in the oncological outcome between 
OBS and conventional BCS with regard to resection margins, timely administration of 
adjuvant therapy, disease-free survival and survival. 
Paper IV: To investigate if there are differences in patient-reported outcome with regard 
to “Satisfaction with Breast”, “Psychosocial Well-being”, Physical Well-being” and 
“Sexual Well-being” among breast cancer patients between patients operated with 
either OBS or conventional BCS. 
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Patients and methods studies I – IV 
This thesis is based on a study-population of patients treated with OBS for early breast 
cancer and DCIS registered in a local research database. Patients in the study-
population were recruited in the Southern Region of Denmark and from a private 
hospital in Copenhagen from 2008 to 2013. In order to avoid a potential selection bias 
due to different indications for surgical technique, we did not compare OBS patients 
to the other patients treated with conventional BCS from the same geographical area. 
Instead, we chose all patients treated with conventional BCS in the Northern Region 
of Denmark, the BCS North cohort, in the same period of time as controls in papers 
III and IV. OBS was not performed in Region North as a routine procedure during the 
study period. In order to identify potential regional differences in routines e.g. adjuvant 
treatment, in paper III, we also collected information for all patients treated with BCS 
in the Southern Region of Denmark. To retrieve comparable data for the oncological 
(III) and patient-reported outcome study (IV) the studies were designed to use data 
from the national DBCG registry for both the study cohort and the control cohort.  
Patients and databases 
Research database 
Patients were consecutively registered from the 1 January 2008 until 31 December 
2013 in a research database when treated with techniques used in OBS (Figure 1). 
Patients registered in the database were diagnosed with primary invasive breast cancer, 
DCIS, sequelae after previous breast cancer surgery or with benign diseases, e.g. giant 
adenomas 92. Data on diagnosis, type of surgery, time of surgery, age as well as pre-, per- 
and postoperative data were recorded, including follow-up visits. All patients had been 
operated with surgical techniques used in reconstructive and aesthetical plastic surgery 
for OBS. Surgery was performed at the Hospital of Southwest Jutland, Esbjerg, at the 
Hospital of South Jutland, Aabenraa, and at the Private Hospital, Hamlet, 
Copenhagen. In total, 236 patients were registered (Figure 1). The research database 
was approved by the Danish Data Protection Agency 93. Data for patients in the 
research database, who were also identified in the DBCG registry 10, were retrieved from 
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the DBCG registry by permission from the Danish Clinical Registries (RKKP), the 
Danish National Board of Health 94.  
 
Figure 1. Breast Conserving Surgery (BCS) and Oncoplastic Breast Surgery (OBS) cohorts. 
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Danish Breast Cancer Cooperative Group registry 
The DBCG registry, a nationwide registry established in 1976, is a clinical database 
receiving data from all departments of radiology, surgery, pathology and oncology 
involved in the diagnosis and treatment of breast cancer in Denmark 10. Data recorded 
include date of diagnosis, tumour characteristics, surgical treatment, oncological 
adjuvant therapy and information on recurrent disease and death. The use of 
oncoplastic surgical techniques has been registered since 1 July 2010. Data on 
postoperative complications are not registered in the DBCG registry.  
Patients in the research database, the BCS North and the BCS South cohorts were 
identified in the DBCG registry by permission from the Danish Clinical Registries, the 
Danish National Board of Health 94. The BCS North cohort, including all patients 
with primary invasive breast cancer treated with BCS in the Region of Northern 
Denmark from 1 January 2008 to 31 December 2013, was identified as a consecutive 
population-based cohort in the national DBCG registry (n=1423, figure 1). The BCS 
South cohort, which included all patients treated with BCS in the Region of Southern 
Denmark from 1 January 2008 to 31 December 2013, were similarly identified in the 
DBCG registry (n=3662). Only data regarding time of surgery, administration of and 
time to initiation of adjuvant therapy were collected for the BCS South cohort. The 
studies in papers III and IV used data collected between 1 January 2008 and 3 January 
2017.  
Study-specific Questionnaire (SSQ) 
Using an SSQ we collected data on patient characteristics regarding body mass index 
(BMI), chest circumference, bra-size, menopausal status, smoking habits, marital 
status, living arrangements and education. These characteristics could possibly 
influence the outcomes of satisfaction and HRQoL evaluated by the Breast-Q 
postoperative module. These data were included in the analyses in paper IV as potential 
confounding factors along with predictive factors retrieved from the DBCG registry. 
Study populations  
Patients - paper I 
Patients with invasive breast cancer were included from the research database between 
January 2008 and December 2010. OBS was performed on 72 patients with a total of 
74 primary tumours (two cases with bilateral breast cancer). Breast size was categorised 
as small, medium or large which correlates to a clinical norm where a small breast is up 
to 250 cc, a medium one is 250–500 cc and a large one is 500 cc or more. For 
descriptive reasons, tumour location was categorised in zones I–IX as described by 
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McCulley and Macmillan (Figure 2) 5. A categorisation of the patients was made as 
guidance for planning and evaluation of the reconstruction based on breast size and 
tumour location into four groups. Groups I to III included medium to large breasts 
with tumours located in the lower part, the mid or upper part, and the central part of 
the breast, respectively. Group IV included small breasts with all possible tumour 
locations. Patients in group I were treated with volume reduction techniques, patients 
in groups II and III were treated mainly with displacement techniques while patients 
in group IV were treated with replacement techniques. 
 
Figure 2. Illustration of the distribution of zones in the breast described by McCulley and MacMillan. 
For all patients, volume reduction, volume displacement or volume replacement 
techniques were used for immediate reconstructions, thus, all operations represented 
what was later defined as level II OBS 1 2 51. Forty-four patients were operated at the 
Hospital of Southern Denmark, Esbjerg, twenty-three patients at Aleris-hamlet 
Privathospitaler, Copenhagen, and five patients at the Hospital of Southern Denmark, 
Aabenraa. 
Patients – paper II 
A subpopulation of 15 patients operated with OBS and whose breasts were 
reconstructed with the tunnelled fasciocutaneous thoracodorsal flap with skin island, a 
replacement technique, were identified in the research database in the period January 
2008 to January 2011. Thirteen patients had small breasts (<250 cc) where no 
contralateral surgery was needed to achieve symmetry, while two patients with 
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medium-sized breasts (250-500 cc), who did not want to have contralateral surgery, 
were operated with this technique. Data were collected consecutively for all patients 
preoperatively and also postoperatively at follow-up visits. All patients were seen at 
follow-up visits after three months, 10 after one year, and 6 after two years by a plastic 
surgeon. Patients were operated at the Department of Surgery, Section of Plastic 
Surgery, Hospital of Southwest Jutland, and at the Department of Plastic and Breast 
Surgery, Privathospitalet Hamlet, Copenhagen, in the period from January 2008 to 
January 2011. 
Patients – paper III 
OBS cohort 
Patients treated with OBS were consecutively registered in the research database at the 
Hospital of Southwest Jutland, which was approved by the Danish Data Protection 
Agency 93, and 236 patients were registered. In all, 197 patients with primary invasive 
breast cancer registered in the research database remained in the OBS cohort after 
exclusion due to the reasons shown in figure 1. These patients underwent surgery in 
the Region of Southern Denmark at the Hospital of Southwest Jutland, Esbjerg, 
between 1 January 2008 and 31 December 2013 or at the Hospital of South Jutland, 
Aabenraa, from 1 October 2010 to 31 December 2013. Patients from Privathospitalet 
Hamlet, Copenhagen, in the period 1 January 2008 to 31 December 2010 were also 
included.  
BCS North and BCS South cohorts 
Patients in the BCS North cohort (n=1423) were identified in the DBCG registry 10 
and treated for invasive breast cancer in the period 1 January 2008 to 31 December 
2013 from a dataset retrieved in January 2014 (figure 1). After exclusion of 24 patients 
with bilateral cancer, 1399 patients remained in the BCS North cohort. Furthermore, 
3662 patients were included in the BCS South cohort. These patients had surgery in 
the Northern and Southern Regions of Denmark, respectively, in the period 1 January 
2008 to 31 December 2013. 
Patients – paper IV 
All patients diagnosed with primary invasive breast cancer treated with BCS in the 
Region of Northern Denmark from 1 January 2008 to 31 December 2013, in the BCS 
North cohort, were identified as a consecutive population-based cohort in the national 
DBCG registry 10 (n=1423) in a dataset retrieved in January 2014 (Figure 3). Patients 
treated with OBS were consecutively registered in the research database, approved by 
the Danish Data Protection Agency 93 at the Hospital of Southwest Jutland, and 236 
patients were registered. At the time of the survey in March 2016, patients not 
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registered with breast cancer (17) and double entries to the database (n=6) were 
excluded as well as patients who at the time of survey had died (n=132) according to 
data from the Danish Cause of Death register 95 . In all, 1504 patients were sent the 
survey, which resulted in 764 patient replies (figure 3).  
 
Figure 3. Breast Conserving Surgery (BCS) and Oncoplastic Breast Surgery (OBS) cohorts. 
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Based on a second DBCG registry 10 dataset retrieved in 2017, patients were excluded 
(n=37) if at the time of the survey they had experienced recurrence of the disease, a 
secondary mastectomy, were registered with bilateral cancer, did not have surgery in 
the period 2008 to 2013 or if they were not registered in the DBCG registry 10. The 
final study-population included 727 patients in all, with 631 and 96 evaluable replies 
in the BCS and the OBS cohorts, respectively (figure 3).  
Patients in the BCS cohort underwent surgery in the Northern region of Denmark. 
Patients in the OBS cohort underwent surgery in the Region of Southern Denmark at 
the Hospital of Southwest Jutland, Esbjerg, (1 January 2008 - 31 December 2013; n = 
40), at the Hospital of South Jutland, Aabenraa (1 October 2010 - 31 December 2013; 
n = 48), or at Privathospitalet Hamlet, Copenhagen (1 January 2008 - 31 December 
2010; n = 8).  
Among the patients in the OBS cohort, 32 had level I surgery. Sixty-four patients had 
level II surgery and 32 of them had contralateral surgery for symmetry. The mean 
follow-up time among all 727 patients was 60.8 months (range 26-100).  
Statistical methods  
Data were analysed using IBM–SPSS Statistics version 24.0, IBM Corp., US. 
Statistical methods paper III 
The OBS and the BCS North cohorts were compared regarding factors that might 
affect the studied endpoints, i.e., patient, diagnostics and tumour characteristics. The 
risk of non-radical primary tumour excision was compared between the OBS and BCS 
North cohort, including all patients in an intention to treat design, i.e. including 
patients who later underwent a mastectomy. A logistic regressions analysis yielded odds 
ratios (ORs) with 95% confidence intervals. The most important prognostic factors 
(Table 1) were selected à priori and included in a second multivariate model.  
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Table 1. Prognostic factors. 
Factor  Category BCS North* OBS** Total 
  n = 1399 n = 197 n = 1596 
     
  Column percent 
Age <50 year  13.9 22.3 14.9 
 ≥50 year - <65 year  51.3 53.8 51.6 
 ≥65 year  34.9 23.9 33.5 
     
Nottingham histological 
grade 
I  29.6 24.9 29.0 
II  36.2 42.1 36.9 
 III  21.2 26.9 21.9 
 Missing 13.0 6.1 12.2 
     
Vascular invasion  No 88.1 76.1 86.6 
 Yes 9.6 18.8 10.8 
 Missing 2.3 5.1 2.6 
     
Focality Unifocal 94.6 92.9 94.4 
 Multifocal (≥2) 2.1 5.6 2.5 
 Missing 3.4 1.5 3.1 
     
Tumour (T) classification 
(mm)  
T1 ≤20  81.7 60.4 79.1 
T2 21-50  17.5 37.1 19.9 
 T3 >50  0.4 0.0 0.4 
 Missing 0.4 2.5 0.6 
     
Node (N) classification  N0 66.1 51.3 64.3 
 N1 25.9 37.6 27.3 
 N2  4.9 4.6 4.9 
 N3 1.9 4.6 2.3 
 Missing  1.1 2.0 1.3 
     
Estrogen receptor status  Negative 13.4 14.7 13.6 
 Positive 86.1 83.8 85.8 
 Missing 0.5 1.5 0.6 
     
HER2-status  Negative 75.5 85.8 76.8 
 Positive 8.6 11.2 8.9 
 Missing  15.9 3.0 14.3 
     
* BCS North = Breast Conserving Surgery North cohort, **OBS = Oncoplastic Breast Surgery cohort. 
Data in the analyses for initiation of chemotherapy and radiotherapy only included 
values from 14 days postoperatively until 180 days postoperatively. Adjuvant therapy 
initiated earlier was regarded as neo-adjuvant therapy, and adjuvant therapy initiated 
later was probably not directed toward the primary tumour or the values were regarded, 
as due to incorrect registration. In these analyses patients who had a mastectomy as a 
secondary surgical procedure were excluded, i.e. these were per protocol analyses. This 
was because a secondary mastectomy would probably greatly affect the time to and also 
indications for adjuvant treatment. However, sensitivity analyses including patients 
who had a mastectomy were also performed. Time to initiation of adjuvant therapy was 
compared between OBS and BCS North patients using a Kaplan-Meier analysis 
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including a log-rank test. Following this, a Cox Proportional Hazards analysis was used 
to calculate hazard ratios (HRs) with 95% confidence intervals. In a second model, 
prognostic factors (Table 1) were included as co-variates together with factors that 
might delay adjuvant therapy, i.e. a non-radical excision, specimen size and axillary 
dissection (data shown in paper III). The HRs can be regarded as a measure of the 
difference between groups in the probability of having started adjuvant therapy at a 
given point in time. Eventually, all selected patients in this sub-analysis received 
adjuvant therapy.  
Disease-free survival, defined as survival without recurrent disease, breast cancer cause 
of death, multiple and breast cancer cause of death and overall mortality were also 
analysed using a Cox Proportional Hazards analysis. The same prognostic factors 
(Table 1) were chosen as co-variates in these analyses. In these analyses, patients who 
had a mastectomy were included, i.e. these were intention to treat analyses, but 
sensitivity analyses were also performed excluding these patients, i.e. per protocol 
analyses (data shown in paper III).  
Additional sensitivity analyses were performed for time to initiation of adjuvant 
therapy, disease-free survival and survival excluding patients in the BCS North cohort 
who were registered in the DBCG registry as having had OBS (n=51). Furthermore, 
additional sensitivity analyses were performed excluding patients who had undergone a 
Level I oncoplastic procedure for the endpoints of non-radical primary tumour 
excision, adjuvant therapy, disease-free survival and survival.  
Statistical methods paper IV 
The OBS and BCS cohorts were compared using univariate logistic regression analyses 
for the scores of each domain in the Breast-Q BCT postoperative module. In the OBS 
cohort, separate analyses were conducted for all patients and for those patients who had 
undergone level II oncoplastic procedures. The scores in the Breast-Q domains (0-100) 
for the BCS cohort were transformed from a linear variable into a binary variable by 
the median score used for the cut-off value for each domain as the dependent variable, 
i.e. scores lower than the median score were considered less favourable and higher scores 
as more favourable. The risk of a better outcome was compared between the OBS and 
BCS cohorts by the logistic regression analysis and yielded OR with 95% confidence 
intervals. Factors that might affect the patient-reported outcome, i.e. patient, tumour 
and treatment characteristics, were selected à priori and included in a second 
multivariate logistic regression model (Tables 2 and 3). We performed sensitivity 
analyses excluding patients treated with OBS registered in the DBCG registry from 1 
July 2010 to 31 December 2013 in the BCS cohort (n = 24). We also compared 
responders (n = 727) to non-responders (n=683) in order to check for potential 
selection bias. This analysis included age at surgery and the same tumour characteristics 
and treatment factors as used in the analyses of responding patients.  
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Table 2. Patient characteristics. 
Factors Category BCS OBS Total 
  n = 631 n = 96 n = 727 
   
  Column percent* 
Age at surgery (year) <50 15.5 25.0 16.8 
 ≥50 - <65 56.6 52.1 56.0 
  ≥65  27.9 22.9 27.2 
     
Menopausal status Pre-menopausal 23.6 34.4 25.0 
 Post-menopausal 73.9 63.5 72.5 
     
Bra size A 8.7 13.5 9.4 
 B 31.2 26.0 30.5 
 C 26.1 24.0 25.9 
 D 18.5 16.7 18.3 
 E 4.1 6.3 4.4 
 ≥F 5.1 8.3 5.5 
 Missing 6.2 5.2 6.1 
     
Chest circumference (cm) ≤82  20.9 21.9 21.0 
 83 - 87 20.0 25.0 20.6 
 88 - 92 13.8 15.6 14.0 
 93 - 97 8.4 7.3 8.3 
 ≥98 15.1 10.4 14.4 
 Missing 21.9 19.8 21.6 
     
BMI < 25 36.8 41.7 37.4 
 25.0 – 29.9 35.3 39.6 35.9 
 ≥ 30 17.6 16.7 17.5 
 Missing 10.3 2.1 9.2 
     
Smoking prior to surgery Never-smoker 40.6 57.3 42.8 
 Ever-Smoker 53.3 42.7 53.6 
     
Smoking at surgery Non-smoker 77.7 86.5 78.8 
 Smoker 19.5 13.5 18.7 
     
Marital status Single 7.9 11.5 8.4 
 Married 68.3 69.8 68.5 
 Separated 0.6 1.0 0.7 
 Divorced 9.2 10.4 9.4 
 Widow 13.3 7.3 12.5 
     
Living arrangement Living alone 23.6 18.8 23.0 
 Cohabiting 69.6 77.1 70.6 
 Others 3.2 1.0 2.9 
     
Education (year) Primary school 20.8 12.5 20.6 
 Secondary school 10.0 12.5 10.3 
 Higher educ* (2-3) 32.3 22.9 31.1 
 Higher educ* (3-5) 31.9 37.5 32.6 
 Higher educ* (5-6) 4.3 7.3 4.7 
     
Column percent does not always add up to 100% as missing data are only shown if >5%. Educ* = education. 
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Table 3. Tumour characteristics and treatment factors. 
Factors Category BCS OBS Total 
  n = 631 n = 96 n = 727 
   
  Column percent* 
Tumour size (mm) T1 ≤ 20 84.0 62.5 81.2 
 T2 21 – 50 15.7 34.4 18.2 
 T3 ≥ 50  0.3 0.0 0.3 
     
Specimen volume (cc) < 50 20.0 15.6 19.4 
 50 - 99 30.7 26.0 30.1 
 100 - 199 33.0 32.3 32.9 
 ≥ 200 14.9 21.9 15.8 
     
Tumour location Upper lateral 37.9 40.6 38.2 
 Upper medial 14.6 8.3 13.8 
 Lower lateral 8.9 9.4 8.9 
 Lower medial 7.0 6.3 6.9 
 Central 6.2 15.6 7.4 
 Overlapping regions 23.8 19.8 23.2 
     
Axillary dissection No 66.2 52.1 64.4 
 Yes 33.8 44.8 35.2 
     
Radiotherapy No 4.4 2.1 4.1 
 Yes 95.6 97.9 95.9 
     
Chemotherapy No 58.6 49.0 57.4 
 Yes 41.4 51.0 42.6 
     
Endocrine therapy No 42.3 34.4 41.3 
 Yes 57.7 65.6 58.7 
     
Immune therapy No 91.1 89.6 90.9 
 Yes 8.9 10.4 9.1 
     
Column percent does not always add up to 100 as missing data are not shown. 
Ethics  
The studies were submitted to The Regional Committee on Health Research Ethics for 
Southern Denmark. Studies I and II were regarded as studies evaluating the quality of 
clinical practice, while papers III and IV where regarded as primary register studies. 
None of these needed approval by the Regional Committee on Health Research Ethics 
for Southern Denmark. Studies III and IV were also submitted for evaluation to the 
Regional Ethical Review Board in Lund, Sweden, as the research was conducted at 
Lund University, Sweden, but their approval was not required (Dnr.2014/882). The 
research database identifying OBS patients was approved by the Danish Data 
Protection Agency 93.  
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Results 
Paper I 
A strategy for implementation of OBS in daily clinical practice was presented. The 
mean age of the 72 patients included was 53 years (range 31-69 years). Two patients 
had bilateral tumours, so the total number of cancers was 74. Surgery was performed 
as planned preoperatively on all but one patient, who had a mastectomy due to an 
unexpected spread of the tumour. Invasive ductal carcinomas comprised 87 % of 
tumours, while 3 % were invasive lobular carcinomas, 6 % were mixed types and 4 % 
were DCIS. The mean tumour size was 21 mm, ranging from 6 to 50 mm. In Table 4 
tumour resections with immediate partial breast reconstruction in relation to tumour 
location (zones) and size of the breast (small, medium and large), weight of specimen, 
methods of reconstruction and contralateral surgery group I–IV are shown. A summary 
of complications to surgery and secondary surgery caused by complications and disease 
control is shown in Tables 5 and 6. 
Table 4. Tumour resections with immediate partial breast reconstruction in relation to tumour location (zones) 
and size of the breast (small, medium and large), weight of resection (grammes), methods of reconstruction 
and contralateral surgery group I–IV 
Group (Breast  
size, zone) 
No Tumour resection  
weight mean (range) 
Reconstruction  
method 
No Contralateral  
surgery 
      
I (medium - large, II–IV) 17 367 g (41–1630) Superior flaps 17 17/17 (100 %) 
      
II (medium - large, V–IX) 25 138 g (27–463) Inferior flaps 16 22/25 (88 %) 
   Superior flaps 4  
   Lateral flaps 1  
   Rotation flap 1  
   Tunnelled LT flapa 2  
   TAP flap 1  
      
III (medium - large, l) 14 83 g (27–124) Inferior flaps 13 14/14 (100 %) 
   Superior flap 1  
      
IV (small breasts, I–IX) 17 55 g (20–127) Tunnelled LT flapa 13 1/17 (6 %) 
   LD flapc 3  
   Rotation flap+LTb 1  
      
Total (groups I–IV, I–IX) 73 157 (20–1630)  73 54/73 (74 %)* 
      
Tunnelled LT flapa: tunnelled lateral fasciocutan thoracodorsal flap with skin island. LTb: lateral thoracodorsal 
flap. LDc: muscle-sparing latissimus dorsi flap. *For one of 72 patients (two patients had bilateral cancer = 74 
tumours) mastectomy was required instead of oncoplastic surgery because of non-radical partial mastectomy.  
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Table 5. Causes of secondary surgery in general anaesthesia. 
Complication Site of complication No Percent 
    
Haematoma Reconstruction 4 (5.4 %) 
 Contralateral breast 3 (4.1 %) 
 Axilla 2 (2.7 %) 
    
Disease control    
Re-resections  7 (9.5 %) 
ALND* due to late positive SN  9 (12.3 %) 
Mastectomy  3 (4.1 %) 
    
Reoperations total  28 (38.3 %) 
ALND: axillary lymph node dissection. n=73. One patient had haematoma on both the reconstructed and 
contralateral breast after reduction mammoplasty, as well as a third haematoma after re-resection because of 
insufficient resection margins. 
Table 6: Complications observed after oncoplastic surgery. 
Site of 
complication 
Haematoma Necrosis Seroma Delayed 
wound 
healing 
Infection Total 
       
Reconstructed 
breast (n=73) 
4 1 0 3 0 8 
       
Donor site 
(n=20) 
0 0 0 0 0 0 
       
Contralateral 
breast (n=53) 
3 0 0 2 0 5 
       
Axilla (n=45) 2 0 1 0 1 4 
       
Total 9 1 1 5 1 n.a. 
       
One patient had a haematoma on both the reconstructed and contralateral breast after reduction 
mammoplasty, whereas another patient experienced delayed wound healing (more than four weeks) on both 
breasts. n.a.: not applicable. 
Paper II 
Fifteen patients, ranging in age from 38 to 65 years (mean 53.5), were included. For 
three patients, the tumour was located in the upper lateral part of the breast; for seven 
patients, in the mid-lateral part of the breast; for two patients, in the medial upper part 
of the breast; and for three patients in the central part of the breast. In three patients, 
partial mastectomy included the NAC. All tumours were invasive ductal carcinomas 
and measured 14–37 mm (mean 22.7) and the weight of the lumpectomy ranged from 
20 to 108 g (mean 54.5). In 11 patients (73%) SNB was positive, and all of them had 
ALND.  
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In all 15 cases the resections margins were per-operatively macroscopically approved by 
the pathologist. However, in four patients (27%) the resection margins were considered 
to be too narrow in the final routine histopathological evaluation and in these four 
patients a re-resection was performed in a second procedure. No secondary 
mastectomies had to be performed because of insufficient resections. 
In the early postoperative period one patient had haematoma in the breast related to 
the reconstruction, and the haematoma was surgically evacuated. Otherwise, no early 
complications occurred. Consequently, no patients had complications leading to any 
delay in the adjuvant therapy. At the follow-up visits after three months and one year, 
one patient reported intermittent pain at the donor site; however, no specific therapy 
had so far been needed. Otherwise, no late surgical complications occurred. One 
patient, however, had recurrence of the tumour with disseminated disease and died 19 
months postoperatively. 
Paper III 
The end points in this paper were: risk of non-radical surgery at the time of partial 
mastectomy, time to initiation of first adjuvant therapy, disease-free survival and mortality.  
The median age of the OBS cohort was 57 years (range 31-80) and of the BCS North 
cohort 61 years (range 24-93). Patients in the OBS cohort, as compared to the BCS 
North, had tumours with a higher average histological grade, their tumours more often 
occurred with vascular invasion, they had a larger number of multifocal tumours, they 
had larger tumours and more often positive lymph nodes as well as tumours with 
negative ER and HER2 receptor status (Table 1). 
Risk of non-radical surgery at the time of partial mastectomy  
The adjusted OR for OBS patients, as compared to BCS North patients, for non-radical 
primary tumour excision was 0.50 (0.29-0.84), thus showing a statistically significant 
lower risk of non-radical resection of the tumour in the OBS cohort (Table 7). 
Table 7. Odds ratio (OR) for non-radical surgery at the time of lumpectomy. 
Cohort All* Radical Non-radical OR OR* 
      
BCS-North  1364 1146 218 (16.0%) 1.00 1.00 
      
OBS 190 171 19 (10.0%) 0.58 (0.36-
0.96) 
0.50 (0.29-
0.84) 
      
Total 1554 1317 237   
      
All* = Data for 42 of 1596 patients were missing. OR = Odds Ratio. OR* = Odds Ratio adjusted for age, 
Nottingham histological grade, vascular invasion, tumour focality, T- and N-status, ER status and HER2- status. 
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Time to initiation of first adjuvant therapy 
Adjuvant chemotherapy 
In the OBS cohort, 48.1% were treated with chemotherapy as the first mode of 
adjuvant therapy, initiated after a median time of 30.0 days, while in the BCS North 
cohort 34.4% were treated after a median time of 38.0 days after surgery (Table 8). We 
found an unadjusted HR at 1.21 (0.96-1.52) and an adjusted HR of 1.14 (0.89-1.45). 
The HR refers to the risk (chance) at any given time point of having received adjuvant 
therapy i.e. a high HR means a lower risk of late initiation. Thus, there was no 
statistically significant difference between the OBS cohort and the BCS North cohort 
in time to initiation of chemotherapy.  
Adjuvant radiotherapy 
In the OBS cohort, 43.2% were treated with radiotherapy as the first adjuvant therapy 
with a median time to initiation of 48.0 days while in the BCS North cohort 51.4% 
were treated with a median time to initiation of therapy of 44.0 days (table 8). The 
adjusted hazard ratio was 0.91 (0.71-1.16), thus, no statistical differences in time to 
initiation of radio therapy were found. 
Disease-free survival  
Concerning disease-free survival, i.e. survival without recurrent disease, the median 
follow-up time for the OBS cohort was 4.1 years (range 0.0-8.9) and for the BCS North 
cohort 5.6 years (range 0.0-9.0). Disease-free survival was lower in the OBS cohort 
compared to the BCS North cohort. We found a hazard ratio of 1.88 (1.00-3.54), but 
the adjusted HR was attenuated, at 1.23 (0.61-2.47) showing no statistical differences 
in disease-free survival between the OBS and BCS North cohorts (Table 9). 
Table 9. Disease-free survival measured as the hazard ratio (HR) for recurrence of breast cancer in the period 
from 1 January 2008 to 3 January 2017. 
Cohort All Recurrences Recurrencies (%) Recurrences/ 
10.000 year 
HR HR* 
       
BCS North 1399 51 3.7 66.5 1.00 1.00 
       
OBS 197 12 6.1 135.6 1.88 (1.00-3.54) 1.23 (0.61-2.47) 
       
Total 1596 63 4.0 73.7   
       
*Adjusted for age, vascular invasion, Nottingham histological grade, ER status and HER2-receptor status, 
tumour focality, T- and N-classification. BCS North = BCS North cohort, OBS = OBS cohort. 
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Survival 
Concerning overall mortality, the median follow-up time was 4.4 years (range 0.0 – 
8.9) for the OBS cohort and 5.7 years (range 0.1-9.0) for the BCS North cohort. The 
median follow-up time for cause-specific mortality was 2.6 years (range 0.7-6.9), and 
3.9 years (range 0.0-7.0), respectively. The adjusted risk (HR) of breast cancer as the 
underlying cause of death in OBS patients as compared to BCS patients was 1.46 (0.52-
4.09) (Table 10). Corresponding HR´s for breast cancer as the underlying or multiple 
cause of death was 0.90 (0.34-2.37), and regarding overall mortality it was 0.90 (0.51-
1.60). This means that no significant differences between OBS and conventional BCS 
were revealed.  
Table 10. Survival measured as hazard ratio (HR) for death due to breast cancer as underlying cause of death 
and breast cancer as underlying or multiple causes 2008-2014, and HRs for overall mortality 1 January 2008 to 3 
January 2017 for Breast Conserving Surgery in Region North of Denmark (BCS North) and Oncoplastic Breast 
Surgery (OBS). Including patients who had a secondary mastectomy i.e. an intention to treat analysis. 
Cause of death Cohort All 
n = 1596 
Death Mortality/ 
10000 year 
HR HR* 
       
Breast cancer as  
underlying cause  
of death 
BCS North 1399 26 47.3 1.00 1.00 
OBS 197 6 100.1 2.18 (0.90-5.32) 1.46 (0.52-4.09) 
Total 1596 32 52.5   
       
       
Breast cancer as  
underlying or multiple 
cause of death 
BCS North 1399 38 69.1 1.00 1.00 
OBS 197 6 100.1 1.48 (0.63-3.51) 0.90 (0.34-2.37) 
Total 1596 44 72.2   
       
       
Overall cause of death BCS North 1399 130 162.3 1.00 1.00 
OBS 197 16 167.9 1.04 (0.62-1.75) 0.90 (0.51-1.60) 
Total 1596 146 162.9   
      
* Adjusted for age, vascular invasion, Nottingham histological grade, tumour focality, T- and N-classification, ER 
status and HER2-receptor status.  
Paper IV 
The final study population included a total of 727 patients with 631 and 96 evaluable 
replies in the BCS and the OBS cohorts, respectively (Figure 3). The total response rate 
for evaluable replies was 48.3% (727/1504), while the response rates for the BCS and 
OBS cohorts were 48.4% (631/1304) and 48.0% (96/200), respectively. The mean 
follow-up time among all 727 patients was 60.8 months (range 26-100). Among 
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patients in the OBS cohort, 32 had level I surgery. Sixty-four patients had level II 
surgery and 32 of them had contralateral surgery for symmetry. 
Patient, tumour and treatment characteristics are shown in Tables 2 and 3 and indicate 
that the patients in the OBS cohort had more advanced cancers than those in the BCS 
cohort. Comparing the responder cohort to the non-responder cohort showed only 
minor differences between the two cohorts, which indicates that the responder cohort 
was representative for the survey population (Table 11.) 
Table 11. Patient and tumour characteristics and treatment factors for the responder and non-responder 
cohorts.  
Covariates Category OBS BCS 
  Responders Non-responders Responders Non-responders 
  n = 96 n = 71 n = 631 n = 612 
   
  Column percent* 
Age at surgery  < 50  25.0 18.3 15.5 12.7 
(years) ≥ 50 - < 65 52.1 52.1 56.6 50.0 
 ≥ 65 22.9 29.6 27.9 37.3 
      
Tumour size (mm) T1 ≤ 20  62.5 63.4 84.0 82.2 
 T2 21 – 50  34.4 33.8 15.7 17.3 
 T3 ≥ 50  0.0 0.0 0.3 0.3 
      
Specimen size  < 50 15.6 12.7 20.0 20.9 
(cm3) 50 - 99 26.0 32.4 30.7 27.8 
 100 - 199 32.3 26.8 33.0 30.9 
 ≥ 200 21.9 25.4 14.9 17.5 
      
Tumour location Upper lateral 40.6 32.4 37.9 41.0 
 Upper medial 8.3 12.7 14.6 11.4 
 Lower lateral 9.4 11.3 8.9 10.8 
 Lower medial 6.3 12.7 7.0 6.2 
 Central 15.6 7.0 6.2 5.4 
 > 1 region 19.8 22.5 23.8 22.1 
      
ALND* No 52.1 59.2 66.2 64.1 
 Yes 44.8 39.4 33.8 35.8 
      
Radiotherapy No 2.1 5.6 4.4 4.2 
 Yes 97.9 94.4 95.6 95.8 
      
Chemotherapy No 49.0 56.3 58.6 69.4 
 Yes 51.0 43.1 41.4 30.6 
      
Endocrine therapy No 34.4 35.2 42.3 40.8 
 Yes 65.6 64.8 57.7 59.2 
      
Immune therapy No 89.6 90.1 91.1 94.3 
 Yes 10.4 9.9 8.9 5.7 
      
ALND*: Axillary lymph node dissection. Column percent does not always add up to 100 as missing data is not 
shown. Patients in the Responder cohort (n = 764) and Non-responder cohort (n = 1504-764 = 740) were 
excluded (Responder cohort (n = 37) and Non-responder cohort (n = 57)) if the patients were not registered in 
the DBCG-registry, did not have surgery in the study period, did not have breast cancer, had bilateral cancers or 
a secondary breast cancer (bilateral event) or if they had a recurrent disease or had undergone a mastectomy 
before the survey (figure 1). * Axillary dissection. 
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The risk of a better outcome was compared between the OBS and BCS cohorts by the 
logistic regression analysis, yielding odds ratios (OR) with 95% confidence intervals. 
OR´s and adjusted OR´s for scores in the Breast-Q modules “Psychosocial Well-
being”, “Physical Well-being”, “Satisfaction with Breasts” and “Sexual Well-being” for 
BCS and OBS levels I+II and BCS and OBS level II are shown in Table 12. We found 
that patients treated with OBS had a better “Psychosocial Well-being” with the 
adjusted OR at 2.15 (1.25-3.69) which was even strengthened for OBS level II alone 
with the adjusted OR at 2.67 (1.37-5.20). However, no significant differences were 
found for the domains “Physical Well-being”, “Satisfaction with Breast” or “Sexual 
Well-being”. 
Table 12. Odds ratios for a high score in Breast-Q modules “Psychosocial Well-being”, “Physical Well-being”, 
“Sexual Well-being” and “Satisfaction with Breasts” for BSC and OBS levels I+II and BCS and OBS level II. 
Domain Cohort All 
 
Below  
median 
Above  
median 
OR OR* 
Psychosocial Well-being BCS 627 311 316 1.00 1.00 
Median = 82 OBS level I+II 95 38 57 1.48 (0.95-2.29) 2.15 (1.25-3.69) 
       
 BCS 627 311 316 1.00 1.00 
 OBS level II 63 23 40 1.71 (1.00-2.96) 2.67 (1.37-5.20) 
       
Physical Well-being BCS 623 277 346 1.00 1.00 
Median = 78 OBS level I+II 95 50 45 0.72 (0.47-1.11) 0.83 (0.50-1.39) 
       
 BCS 623 277 346 1.00 1.00 
 OBS level II 63 32 31 0.78 (0.46-1.30) 0.94 (0.50-1.74) 
       
Satisfaction with Breast BCS 626 308 318 1.00 1.00 
Median = 74 OBS level I+II 95 48 47 0.94 (0.61-1.45) 0.95 (0.57-1.59) 
        
 BCS 626 308 318 1.00 1.00 
 OBS level II 63 29 34 1.13 (0.67-1.90) 1.25 (0.67-2.33) 
       
Sexual Well-being BCS 431 205 226 1.00 1.00 
Median = 58 OBS level I+II 75 33 42 1.15 (0.71-1.89) 1.42 (0.78-2.58) 
       
 BCS 431 205 226 1.00 1.00 
 OBS level II 50 21 29 1.25 (0.69-2.27) 1.86 (0.90-3.83) 
*Adjusted for age, follow-up time, menopausal status, T-classification, lumpectomy size, tumour location, bra 
size, chest measurement, BMI, radiotherapy, chemotherapy, endocrine therapy, immunotherapy, axillary 
clearance, smoking, marital status, living arrangement and education. 
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Discussion 
The aim of this thesis was to describe and evaluate the strategy for implementation of 
OBS. OBS was implemented in a collaboration between breast surgeons and plastic 
and reconstructive surgeons in a daily clinical setting and applied to a broad, unselected 
population of breast cancer patients. The results show in summary, that 
implementation of OBS in the daily clinical setting is feasible without impairing the 
oncological outcome of the treatment of breast cancer and indicate that OBS improves 
the HRQoL in regard to psychosocial well-being compared with conventional BCS, 
despite involving more extensive surgery. 
Implementation of oncoplastic breast surgery 
The surgical aims of OBS are to achieve radical cancer surgery as well as a good aesthetic 
and functional outcome and thereby improve the outcome of surgical treatment of 
breast cancer 3, 82, 96.  
In paper I we present a strategy for implementation of OBS designed to meet those 
aims, along with an evaluation of the strategy and results of surgery 46. 
The purpose of the first study was to present and evaluate the strategy for 
implementation of OBS with regard to the feasibility of a surgical strategy designed to 
include a wide range of patients with variations in breast size, tumour size, and location 
of tumour, and to evaluate the postoperative outcomes of surgery. The OBS cohort in 
paper I included 72 patients with small to large breasts, and tumours of various sizes 
and locations within the breast, thus reflecting the general variations in breast cancer 
patients. We found the study cohort were compatible with patients in previous studies 
regarding tumour type, location and size 2, 4, 5, 49, 50, 97-99. In one of their first studies, 
McCulley and MacMillan 5 evaluate 50 patients with tumours located in all quadrants 
where tumour resection was followed by immediate reconstruction using volume 
reduction and displacement techniques, while Meretoja et al 49 in 2010 evaluated 90 
patients operated for OBS, mainly reduction mammoplasties, although they also 
included some patients with DCIS. 
Various methods of reconstruction were used in the study in paper I, including volume 
reduction, volume displacement and volume replacement techniques, demonstrating 
70 
that surgeons performing oncoplastic breast surgery require knowledge of and 
experience with many reconstructive techniques 2, 4, 5, 34, 44, 46, 50, 53, 62, 64, 68, 97, 100, 101.  
An obvious concern is that OBS with immediate partial reconstruction involving 
internal or external flaps and possibly bilateral surgery could be followed by an increase 
in postoperative complications compared with unilateral conventional BCS. An 
increase in postoperative complications could lead to delay in administration of 
adjuvant therapy, possibly impairing the prognosis 69, 102.  
On evaluating the postoperative results in study I we noted haematomas requiring 
surgery in 12 % of cases, of which 5 % were located in the reconstructed breast, 4 % 
in the contralateral breast and 3 % in the axilla. No flap necrosis was observed. These 
results are consistent with previously reported rates of early postoperative complications 
for OBS 4, 65, 99, 100, 103. In a recent study by Crown et al. evaluating postoperative 
complications for 273 BCS patients compared with 288 OBS patients, they found 
complication rates of 17.9% and 8%, respectively, i.e. considerably lower complication 
rates for OBS 104. 
With regard to the timely administration of adjuvant therapy in study I, four patients 
(6%) had a delay in their adjuvant therapy due to postoperative complications (wound 
healing problems) 46. A delay was considered to have occurred when adjuvant therapy 
was administered later than four weeks postoperatively. Such delays have also been 
reported in previous studies, 49, 99, 105. In the study by Meretoja et al. 49 2% of patients 
experienced a delay in adjuvant treatment due to postoperative complications and in 
the review by McIntosh 99 of studies on therapeutic mammoplasties they found a delay 
in adjuvant treatment in five studies of between 1.9% and 6% of patients.  
Although recognising that our sample in study I was small, our results indicate that 
complications after OBS have little negative impact on the timely administration of 
adjuvant therapy. In our study evaluating oncological outcomes for OBS compared 
with conventional BCS (paper III), we did not find any statistically significant 
differences between the OBS and BCS cohorts with regard to delay in administration 
of adjuvant therapy 106.  
Furthermore, in paper I, we noted that we had positive resection margins in ten of our 
patients (14 %) for which seven (10 %) required re-resection and three (4 %) required 
mastectomy. This result is equal to or better than figures reported in previous studies 2, 
4, 49, 98, 99, 107, 108. Mertoja et al. 49 found that 16.2% of 90 patients treated with OBS had 
positive resection margins, while Clough et al. 2 reported positive margins in 13.%. The 
favourable results are supported by our findings in study III where OBS was 
accompanied 10% positive margins, which was statistically a significantly better 
outcome for primary radical resection compared with conventional BCS (Table 7) 106. 
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Another aspect of OBS is whether to perform contralateral surgery for better symmetry 
in the same procedure as a partial mastectomy and immediate reconstruction, or if it is 
preferable to perform this in a later procedure. This is debated as postoperative 
radiation therapy can cause subsequent shrinkage due to fibrosis or chronic oedema 
leading to an increase in breast volume causing asymmetry months after surgery 3, 105, 
109. We chose to perform contralateral surgery in the same procedure as partial 
mastectomy, where partial reconstruction was carried out with volume reduction or 
displacement techniques. During our observation period of more than two years on 
average, reported in paper I, a supplemental corrective procedure due to asymmetry 
had to be carried out just for one patient. This supports the use of immediate 
contralateral surgery and the findings are consistent with previous studies 2, 4, 5, 49. 
In study I, a total of 946 women had surgery due to breast cancer. Of these patients, 
53.8% (n=509) had conventional BCS, 38.6% (n=365) mastectomy, and 7.6% 
(n=72) OBS. All of the latter had OBS level II. Although the study does not include 
level I OBS, the low percentage of patients operated with OBS indicates that it is 
definitely not the case that all patients that would be suitable for OBS are presented 
with this option. This view is supported by Urban et al. 7 and Baildam 6 who reported 
that up to 30 % of patients treated using BCS experience deformities that require 
complementary surgery. This is also indicated in the recent study by Crown 104. If more 
women were presented with the option of OBS, complementary surgery after 
conventional BCS could be reduced to a minimum. 
A limitation of study I is that, at the time of initiation in 2008, i.e. when OBS patients 
were included in the research database, there was no international consensus regarding 
the definition of OBS 1, 2, 51. This means that it was not possible to categorise our 
patients and the surgical techniques used based on an existing consensus definition, 
making it difficult to compare the results to other studies. However, the reconstructive 
techniques included in the study were later defined as level II OBS 1. Thus patients 
treated with level I OBS were not included in study I.  
In summary, with surgery performed as planned in 73 of 74 operations we found 
implementation of OBS in a daily clinical setting both feasible and safe. With the 
presented surgical strategy we found no increase in non-radical primary surgery or 
postoperative complications, nor any delay in administration of adjuvant therapy. 
However, the results in study I indicate that far from all patients suitable for OBS are 
considered for this treatment. 
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Introducing a modified replacement technique for 
partial breast reconstruction 
In our study (paper II) we introduced the use of a tunnelled fasciocutan thoracodorsal 
flap with a skin island as a modified replacement technique for partial breast 
reconstruction 110-112. The technique was used for women with small breasts where the 
tumour was located in the lateral or central parts of the breast and where skin, and 
sometimes the NAC, overlying the tumour were resected.  
Immediate reconstruction after partial mastectomy in women with small breasts (<250 
cc) represents a challenge as not enough tissue is left for reconstruction with volume 
reduction or volume displacement techniques to reach an acceptable aesthetic outcome. 
The alternative to unfavourable results after partial mastectomy followed by radiotherapy 
in these women has so far been mastectomy with or without immediate or delayed total 
reconstruction. To reconstruct these defects, OBS with replacement techniques by use of 
external flaps thus constitutes an interesting avenue of refinement in BCS 113.  
The technique shows a low postoperative complication rate with only one haematoma 
requiring surgery compared with previous studies 101, 114. Munhoz et al. 114 found in 
their study, including 34 patients with immediate partial breast reconstructions with a 
lateral thoracodorsal fasciocutaneous flap, complications in 11.8% connected to the 
flap, and overall complications affecting 38.2% of patients, while Kijima et al. 101 found 
complications affecting 18.8% of patients with skin necrosis. A low complication rate 
is important so that the adjuvant therapy can be instituted without delay, which 
actually was achieved in our series of patients. Regarding radical surgery, we had four 
re-resections due to positive resection margins (27%), which is higher than expected, 
but no mastectomies 102. Repositioning the flap after re-resection did not impair the 
final outcome regarding the breast configuration. Despite adequate margins and early 
adjuvant therapy within a few weeks, one patient died due to disseminated disease after 
19 months. There were no signs of local recurrence and presumably the patient already 
had disseminated micro metastases from the start.  
However, the study has a limitation. The study sample was small with only 15 patients: 
13 patients with small breasts and two patients with medium-sized breasts, selected as a 
subpopulation of level II OBS patients. A larger sample might have shown a different 
outcome. 
Although we find this flap very useful it is important, when considering reconstruction 
using this flap, to ensure that the volume of the flap matches the volume of the excised 
specimen. If it is anticipated that the volume of the flap will be too small, another 
method of reconstruction should be considered to prevent an unacceptable outcome. 
In such cases, reconstruction with a TAP flap 52, 68, a ms-LD flap 34 or even a 
microvascular free flap might be alternatives. 
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Oncological outcomes of OBS compared with 
conventional BCS 
In summary, we found a statistically significant lower risk of non-radical primary 
tumour excision for patients treated with OBS, including levels I and II compared with 
conventional BCS (paper III). Regarding the time to initiation of the first mode of 
adjuvant therapy, disease-free survival, or survival, we found no statistically significant 
differences. Sensitivity analyses including only level II OBS did not alter these results. 
Thus, our results indicate that OBS is an oncologically safe procedure.  
Previous studies have documented that the oncological safety of BCT equals that of 
mastectomy 75, 76, 115, 116. Many studies address indications for OBS, surgical techniques, 
and complication rates 2, 4, 44, 46, 53, 103, 117, 118, but few studies have evaluated the safety 
of OBS with regard to earl 47, 69, 102, 119-121, and especially long-term, oncologic outcomes 
47, 48, 66, 118, 122 . 
Radical primary excision 
In cases where the size of the tumour in relation to the size of the breast is small, tumour 
excision can often be performed with sufficient margins without applying oncoplastic 
techniques 2, 46, 100. In our study (paper III), the rates for non-radical primary tumour 
excision were lower for OBS (10%) compared to conventional BCS patients (16.0%). 
The definition of what is regarded as radical excision in BCS is often missing in 
published articles 32, 123, and the widths for appropriate negative margins are debated. 
Najafi et al. 124 reported results from 10 studies in 2015 with positive excision margins 
varying from 3.0% to 22.2% for patients operated with OBS, while De la Cruz et al. 
102 in their review including 55 studies found positive excision margins in 10.8% of 
patients. Regarding positive resection margins for conventional BCS, Lovrics et al. 
reported a rate of 26% in a study including 489 patients 125. Compared with 
conventional BCS, we found a statistically significant lower risk for non-radical primary 
tumour excision for patients treated with OBS. This result is in line with several 
previous studies, suggesting that applying oncoplastic surgery does not compromise 
primary excision margins 102, 107, 126.  
Timing of adjuvant therapy 
It is a concern that more extensive surgery could lead to delay in the initiation of 
adjuvant therapy, thereby possibly impairing the oncologic outcome 2, 69, 107. Few 
studies have addressed the possible delay of initiation of adjuvant therapy after OBS. 
In the recent study by Klit A. et al. 74, delay following OBS, specifically compared with 
conventional BCS and mastectomy, was investigated showing there was no delay in the 
initiation of adjuvant chemotherapy for patients treated with OBS. Studies by Kahn et 
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al. 127 and Dogan et al. 128 showed no delay in initiation of chemotherapy after OBS, 
while Hillberg et al. 69 found 8.2% of 150 included patients experienced a delay in the 
initiation of radiotherapy due to postoperative complications. A study by Clough et al. 
2 reported that surgical postoperative complications after OBS had a negative impact 
by delaying adjuvant therapy in 1.7% of 175 patients. It is generally agreed that to have 
the best effect, adjuvant chemotherapy should be initiated within a maximum of 12 
weeks after surgery 70-72. Other results support that this is also true for radiotherapy 73. 
Furthermore, studies confirm that the time to initiation of adjuvant chemo- and 
radiotherapy has an impact on disease-free survival and survival 71-73, although Barbieri 
et al. 129 and more recently van Maaren et al. 130 found that a delay in the administration 
of radiotherapy did not increase the risk for local relapse. These studies indicate that 
OBS does not lead to a delay in initiating adjuvant therapy. 
Our results showed no significant differences in time to initiation of the first mode of 
adjuvant therapy - either chemotherapy or radiotherapy. Our results thus support the 
results of previous studies. To ensure that these results were not reflecting regional 
differences in time to initiation of adjuvant therapy, we also investigated the time to 
adjuvant therapy in the BCS South cohort. We found differences in time to initiation 
of adjuvant therapy when comparing the OBS cohort to the BCS South cohort, with a 
shorter time to chemotherapy, but a longer time to radiotherapy. However, our 
interpretation is that these differences in time may be due to logistic reasons in the 
planning of treatment in the region rather than reasons caused by surgery alone or 
complications of surgery.  
Disease-free survival 
Although OBS has been increasingly implemented in the last two decades as an option 
for BCT, only a few studies have addressed disease-free survival and survival. With 
recurrence rates at 3.65% for conventional BCS, our observations are in line with 
results published in other studies 102 . 
Recurrence rates for patients treated with OBS have been reported to vary from 1.8% 
to 16% 47, 48, 117, 118, 123, and in a review by De la Cruz et al. 102, rates were 6.0% for local 
recurrence and 11.9% for distance recurrence with an observation period of more than 
five years. The percentage of recurrences in breast cancer patients treated with OBS in 
our study was 6.1% at a median follow-up of 4.1 (0.0-8.9) years, which is compatible 
with previously reported results 102, 118. Although the crude HR seems to reveal 
differences in recurrence, the adjusted analyses led to a marked attenuation of the risk. 
This was probably due to comparatively disadvantageous prognostic factors in OBS 
patients, such as tumours of higher grade, the presence of vascular invasion, larger 
tumours, and a more advanced nodal status. In summary, we did not find significant 
differences in disease-free survival between patients treated with OBS or conventional 
BCS. Our results are thus compatible with the results of Carter et al. 118. 
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Survival 
There are few studies addressing survival for patients treated with OBS 102, 118, 123. The 
overall survival, with a mean follow-up time of 50.5 months, for patients treated with OBS 
was reported to be 95% in a review including 6011 patients 102, and another study showed 
no significant differences in overall survival when comparing OBS with conventional BCS 
118. Our results are in line with these results, showing no statistically significant differences 
between OBS and BCS patients with regard to mortality (paper III) 106.  
Patient-reported outcomes of OBS compared with 
conventional BCS 
In this study, we evaluated the patient-reported outcome of OBS compared with BCS 
using the Breast-QTM BCT postoperative module. We found that patients treated with 
OBS had a better outcome for the domain “Psychosocial Well-being”. However, no 
significant differences were found for the domains “Physical Well-being”, “Satisfaction 
with Breast” or “Sexual Well-being”. 
The quality of the health care services provided needs attention. Consequently, there is 
now an increasing demand to evaluate how patients perceive the results of treatment, 
i.e. PRO 131-133. In study IV we took advantage of Breast-Q TM, which can be used as a 
standardised and validated instrument for evaluation of HRQoL in patients operated 
for breast cancer 90, 134-136. The Breast-Q TM BCT pre- and postoperative modules were 
introduced in 2015. One year later, O´Connell et al. 131 published their initial 
experience with the full BCT postoperative module including 200 patients, thus 
establishing a benchmark for future research. However, few studies have addressed the 
HRQoL outcome of conventional BCS 90, 131, 132 and OBS 137 or both. Compared with 
previous studies, patients included in the OBS cohort in study IV represent the full 
spectrum of OBS, i.e. levels I and II surgery. The sample is therefore not restricted to 
one surgical procedure such as the therapeutic mammoplasty technique 137. 
In the domain “Psychosocial Well-being” we found a median score of 82, similar to the 
results of O´Connell 131 and Dahlbäck 138 using Breast-QTM for evaluation of the outcome 
of BCT, while Langendiik 139 found a mean score of 70.1 and Vesprini 132 of 73.5. In our 
study we found a statistically significant better outcome for the OBS cohort, including 
levels I and II surgery, compared with the conventional BCS cohort. The differences were 
strengthened by including only level II surgery from the OBS cohort.  
In their analyses of the domain “Physical Well-being”, Langendjik 139 and Vesprini 132 
found mean scores of 71.2 and 74, respectively. A slightly higher score of 75 was 
reported by O`Connell 131. The median score of 78 in our study (paper IV) reflects a 
low grade of physical discomfort and there was no statistically significant difference 
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between the OBS and BCS cohorts. A lower score for the OBS cohort might have been 
expected, particularly in cases of level II surgery as this surgery is more extensive and 
often involves the contralateral breast. However, the results indicated the opposite since 
there was a slight difference in the figures, indicating better outcomes for OBS 
compared with BCS. 
In the analysis of the domain “Satisfaction with Breast” Vesprini 132 and Langendjik 139 
found mean scores of 59.3 and 65.7, respectively, while Dahlbäck 138 and O´Connell 
131 found median scores of 66 and 68, respectively. Hence, our median score of 74 in 
the present studies is higher than those reported previously and indicates a higher degree 
of satisfaction with the breast. High scores generally imply that possible differences are 
more difficult to detect and, consequently, we found no difference between OBS and 
BCS. However, when only level II surgery was considered, a tendency toward a better 
outcome in the OBS group was noted. 
The domain “Sexual Well-being” had a markedly lower median score of 58 and, 
furthermore, the response rate was low at 69.6%. This pattern has also been seen in 
similar studies and it seems to be a general issue for this domain 131, 132, 139. Therefore, 
the results must be interpreted with caution. We found no difference between the OBS 
and BCS cohorts. However, when only level II surgery was considered, a slight 
tendency toward a better outcome in the OBS group was noted. 
In summary, the results show that patients treated with OBS reported statistically better 
psychosocial health than those treated with conventional BCS. Patients treated with 
OBS also scored slightly higher for the domains “Satisfaction with breasts” and “Sexual 
Well-being”, particularly when the analyses only included level II OBS, although the 
difference was not statistically significant. Notably, the results in the domain “Physical 
Well-being” showed no significant differences despite the fact that patients treated with 
OBS had more extensive and often bilateral surgery. 
Methodological issues and limitations with regard to 
oncological and patient-reported outcome studies 
A methodological issue to be considered is the definition of OBS. In studies published 
in the last few decades, the definition of OBS has varied, making it difficult to compare 
the outcome results from different studies 1 51 56. When we initiated registration of 
patients treated with OBS in the research database there was no clear definition of OBS. 
What we defined as OBS was immediate partial reconstruction with the use of the 
surgical techniques of volume reduction 4, volume displacement 65 and volume 
replacement 52, 62, 63. This was what we later defined as level II OBS. In studies III and 
IV, we have based our definition on the one proposed by Clough et al. 51 which is 
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widely accepted. In the publication of 2019 by Chatterjee et al.1, a consensus definition 
and classifications system, developed by the American Society of Breast Surgeons, was 
presented which was strongly influenced by Clough’s definition 51. By using a widely 
accepted definition of OBS we hope that the results from the present studies may be 
used for comparison with future studies. 
Regarding paper IV, another methodological issue to be considered is the PROM 
instrument chosen. The Breast-Q TM BCT module is now widely accepted since it is a 
validated PROM instrument. Hence, we chose the Breast-QTM BCT postoperative 
module for the evaluation of patient-reported outcomes comparing OBS with 
conventional BCS 134, 135, 140 .  
Papers III and IV do have some limitations due to their designs. Implementing OBS in 
the treatment of breast cancer includes patients in the OBS cohort who, without the 
availability of OBS, would have been treated with mastectomy. This may have led to 
relatively more advanced tumours in the OBS group. However, we included tumour 
size and specimen size in different models, and we believe that this has reduced a 
potential selection bias.  
In order to avoid another form of selection bias, we did not compare patients treated 
with OBS to patients treated with conventional BCS from the same geographic area. 
This would have led to potential confounding due to indication bias, as the indication 
for OBS surgery may affect oncologic safety. However, comparing OBS patients from 
one geographic area with BCS patients from another area can introduce a bias related 
to systematic differences between the areas, and not primarily between OBS and BCS 
patients. In paper III we found differences between the two geographical areas regarding 
time to initiation of adjuvant therapy. We found differences in time to initiation of 
adjuvant therapy comparing the OBS cohort to the BCS South cohort, with a shorter 
time to chemotherapy but a longer time to radiotherapy as the first mode of adjuvant 
therapy expressed by median and mean days. It is our interpretation that this difference 
was due to logistic reasons rather than patient and tumour characteristics or the results 
of surgical treatment.  
In an effort to avoid misclassification of confounding factors, i.e. differences in 
classification of data, all patients included in the studies were identified in the DBCG 
registry, and all data were selected from the same registry, except for data collected by 
the Breast-Q and the SSQ. Because the classification and registration of data in the 
DBCG registry were performed according to national guidelines, we believe that data 
for the cohorts are reliable and comparable. This is supported by a recent study by 
Cronin-Fenton et al. where the authors conclude that DBCG data are valid for 
epidemiological studies of breast cancer treatment 141.  
In paper III we have several end points, and the risk of a type I error, i.e. a rejection of 
a true null hypothesis (false positive results), must be considered in the statistical 
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analyses. However, the results of all the different analyses support that there are no 
significant differences in the oncologic outcome. Finally, it must be kept in mind that 
the statistical power of the results in the analyses of disease-free survival and all survival 
analyses was very limited. Hence, it is possible that non-significant differences in the 
analyses on recurrent disease and survival are due to poor statistical power. Concerning 
recurrent disease and survival, larger studies with longer follow-up are needed. 
In paper IV, the response rate and non-responders may be an issue. Response rates in 
other surveys are reported to be between 31% 132 and 76% 138. With a total response 
rate in our study of 48.3 % for evaluable replies (OBS cohort 48.4%, BCS cohort 
48.0%) we find our response rate acceptable. The analysis comparing patients in the 
responder and the non-responder cohorts showed only minor differences, that is, the 
responder cohort is considered representative of the survey cohort, showing no selection 
bias.  
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Conclusions 
Paper I: 
It is feasible and safe to implement OBS in daily clinical practice based on a thoroughly 
planned strategy for immediate partial breast reconstruction with a wide range of 
variations in tumour size, tumour locations and breast size. 
 
Paper II: 
The tunnelled lateral fasciocutaneous flap with a skin island is a versatile and safe 
procedure in immediate partial breast reconstruction in patients with small or medium-
sized breasts, provided the tumour is located in the lateral or central parts of the breast. 
 
Paper III: 
The study found a lower risk of non-radical primary tumour excision for patients 
treated with OBS compared with conventional BCS. The results showed no statistically 
significant differences in oncologic safety regarding time to initiation of the first mode 
of adjuvant therapy, disease-free survival, or survival. Thus, the results of this study 
support the oncologic safety of OBS. 
 
Paper IV 
The study indicates better outcomes of HRQoL for breast cancer patients treated with 
OBS as compared with patients treated with conventional BCS. There was no increase 
in physical discomfort among OBS patients, despite their more extensive surgery.  
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Future perspectives and considerations 
Since the early start of the implementation of OBS in Denmark at our clinic and a few 
others, OBS has now become recognised as a valuable concept for expansion of 
conventional BCS. OBS is now regarded as an integral part of breast cancer surgery by 
the Danish National Board of Health11. In the guidelines of the National Board of 
Health for Plastic and Reconstructive Surgery, have appointed seven centres to perform 
OBS, while guidelines by the National Board of Health for Breast Surgery have 
appointed eight centres 11. These centres are distributed with at least one centre in each 
of the five Danish Health care regions. In 2010 a guideline for OBS was introduced by 
DBCG and in July 2010 DBCG included the registration of OBS surgery in its registry. 
Special coding for the different types of operations in OBS has been developed which 
in turn is linked to the DRG classification system and thereby to charges. The DRG 
charges aim to reflect the use of resources for each type of surgical procedure with the 
intention to correlate this to the financial reimbursement for the operations provided 
in OBS. 
However, many women in Denmark are still not offered OBS as an option for the 
treatment of breast cancer although they would have benefited from it. This is due to 
several issues.  
One issue is the selection of patients for OBS. Although “we are all surgeons”, e.g. 
breast and plastic surgeons, we are trained differently and have different competence 
profiles and approaches 142, 143. Compared with plastic surgeons, breast surgeons may 
have difficulty evaluating whether patients will – or will not - benefit from OBS i.e. 
achieve better outcomes after partial mastectomy with or without OBS. Furthermore, 
breast surgeons have less training in recognising the different possibilities for 
reconstruction after partial mastectomy. On the other hand, plastic surgeons are usually 
not as familiar as breast surgeons with the oncological aspects related to the treatment 
including adjuvant therapy. This means it is important that all patients are seen by 
surgeons, with competences in both plastic surgery and oncological breast surgery at 
the time surgery is planned. A primary evaluation by a breast surgeon alone renders a 
risk that too few patients will be considered for OBS. 
Another issue is the organisation of the surgical treatment of breast cancer in Denmark. 
As mentioned above, treatment of breast cancer requiring primary reconstruction 
including OBS is limited by the National Board of Health 11 to eight breast surgery 
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centres in Denmark. However, in all, 12 centres treat breast cancer (2018). This means 
that patients diagnosed with breast cancer at a centre where OBS is not possible should 
be referred to a centre where it is an option – or should await a consultation with a 
plastic surgeon. This requires that breast surgeons understand the options of OBS and 
primary reconstruction as alternatives to conventional partial mastectomy and 
mastectomy. This underlines the importance of continued education of all surgeons 
involved in the treatment of breast cancer in all centres.  
A third issue is information given to patients. Most women know, even before a 
personal diagnosis of a breast cancer, that the treatment of breast cancer is surgery and 
that it is usually followed by radio-therapy and chemotherapy. They know that surgery 
may mean either mastectomy or BCS. However, most women do not know about OBS. 
The diagnosis of breast cancer always comes as a surprise – to many as a shock – 
followed immediately by a wish for treatment to “get rid of” the cancer. The elucidation 
and diagnosis of breast cancer must be finished within two weeks from referral, while 
treatment of breast cancer must be initiated within two weeks of diagnosis, and three 
weeks if assistance from a plastic surgeon is needed, according to the Danish national 
guidelines 11. This is a hard period for the patient, and to examine different surgical 
treatment options by themselves is hardly realistic. This is certainly not the time when 
the patients’ first thoughts are about the aesthetical and functional outcomes. As a 
consequence of this, patients do not know about – and do not ask for – OBS as an 
option for surgical treatment. This underlines the importance of information given to 
newly diagnosed patients – and women in general.  
An important topic for future research is the cost-effectiveness of OBS. At first glance 
the impression is that OBS is very resource- and time-consuming, both in the out-
patient setting and in the operating theatre, often requiring two surgeons. Furthermore, 
the number of days in hospital and other costs of care may seem to be higher compared 
with conventional BCS. However, the costs for corrective procedures and later 
secondary reconstructive surgeries and expenses related to impaired HRQoL may offset 
these differences in expenses, even to the advantage of OBS. 
In conclusion, it is crucial to advocate continued education of breast and plastic 
surgeons, even closer cooperation between breast and plastic surgeons engaged in the 
surgical treatment of breast cancer, better organisation of treatment of breast cancer 
with full and appropriate implementation of OBS 144, more and better information will 
be given to patients— and women in general— and continued research to ensure our 
patients receive the maximum benefit. 
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